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A B S T R A C T
Background
Diabetes has long been recognised as a strong, independent risk factor for cardiovascular disease, a problem which accounts for
approximately 70% of all mortality in people with diabetes. Prospective studies show that compared to their non-diabetic counterparts,
the relative risk of cardiovascular mortality for men with diabetes is two to three and for women with diabetes is three to four. The two
biggest trials in type 2 diabetes, the United Kingdom Prospective Diabetes Study (UKPDS) and the University GroupDiabetes Program
(UGDP) study did not reveal a reduction of cardiovascular endpoints through improved metabolic control. Theoretical benefits of the
peroxisome proliferator activated receptor gamma (PPAR-gamma) activator rosiglitazone on endothelial function and cardiovascular
risk factors might result in fewer macrovascular disease events in people with type 2 diabetes mellitus.
Objectives
To assess the effects of rosiglitazone in the treatment of type 2 diabetes.
Search methods
Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library.
Selection criteria
Studies were included if they were randomised controlled trials in adult people with type 2 diabetes mellitus and had a trial duration
of at least 24 weeks.
Data collection and analysis
Two authors independently assessed trial quality and extracted data. Pooling of studies by means of fixed-effects meta-analysis could
be performed for adverse events only.
Main results
Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy was four years
with a median of 26 weeks. Published studies of at least 24 weeks rosiglitazone treatment in people with type 2 diabetes mellitus did
not provide evidence that patient-oriented outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life
are positively influenced by this compound. Metabolic control measured by glycosylated haemoglobin A1c (HbA1c) as a surrogate
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endpoint did not demonstrate clinically relevant differences to other oral antidiabetic drugs. Occurrence of oedema was significantly
raised (OR 2.27, 95% confidence interval (CI) 1.83 to 2.81). The single large RCT (ADOPT - A Diabetes Outcomes Progression
Trial) indicated increased cardiovascular risk. New data on raised fracture rates in women reveal extensive action of rosiglitazone in
various body tissues.
Authors’ conclusions
New studies should focus on patient-oriented outcomes to clarify the benefit-risk ratio of rosiglitazone therapy. Safety data and adverse
events of all investigations (published and unpublished) should be made available to the public.
P L A I N L A N G U A G E S U M M A R Y
Rosiglitazone for type 2 diabetes mellitus
Diseases of the heart and blood vessels account for approximately 70% of all mortality in people with diabetes. Compared to their
non-diabetic counterparts the relative risk of mortality caused by disorders of the heart and blood vessels is two to three for men and
three to four for women with diabetes. Type 2 diabetes is mainly characterised by a reduced ability of the hormone insulin to stimulate
glucose uptake in body fat and muscles (insulin resistance) and affects most people suffering from diabetes. Several medications are on
the market to treat diabetes, amongst them rosiglitazone as a member of the ’glitazones’ reduced risk markers for diseases of the heart
and blood vessels. Since the two biggest trials in people with type 2 diabetes showed that improved blood glucose alone is not enough to
reduce the risk of the above mentioned diseases we looked for longer-term studies investigating 24 weeks as a minimum of rosiglitazone
treatment on patient-oriented outcomes. As patient-oriented outcomes we defined mortality, complications of diabetes, side effects of
the medication, health-related quality of life, costs and metabolic control (lowering of blood glucose to near normal levels).
Eighteen trials randomised 3888 people to rosiglitazone therapy. The longest duration of rosiglitazone treatment was four years, most
trials lasted around half a year. Unfortunately, the published studies of at least 24 weeks rosiglitazone treatment in people with type 2
diabetes mellitus did not provide relevant evidence that patient-oriented outcomes are positively influenced by this agent. The chance
of developing oedema was approximately doubled, the risk of cardiovascular diseases increased. The single large randomised controlled
trial showed evidence of raised cardiovascular risk after rosiglitazone treatment. Moreover, new safety data show increased numbers of
broken bones in women. This finding was published years after approval of this agent by drug regulatory authorities. New ways of
exploring drug effects, for example by early long-term studies in many people, as well as public access to all safety data of published
and unpublished investigations have to be established.
B A C K G R O U N D
Description of the condition
Diabetes mellitus is a metabolic disorder resulting from a defect in
insulin secretion, insulin action, or both. A consequence of this is
chronic hyperglycaemia (that is elevated levels of plasma glucose)
with disturbances of carbohydrate, fat and protein metabolism.
Long-term complications of diabetes mellitus include retinopa-
thy, nephropathy and neuropathy. The risk of cardiovascular dis-
ease is increased. For a detailed overview of diabetes mellitus,
please see under ’Additional information’ in the information on
the Metabolic and Endocrine Disorders Group in The Cochrane
Library (see ’About’, ’Cochrane Review Group (CRGs)’). For an
explanation of methodological terms, see the main glossary in The
Cochrane Library.
There are two main types of diabetes mellitus, type 1 (formerly
termed insulin-dependent diabetes mellitus) and type 2 (formerly
termed non-insulin dependent diabetes mellitus):
Type 1 diabetes mellitus
Type 1 diabetes is a chronic disease characterised by hypergly-
caemia due to absolute deficiency of insulin secretion which is
caused by autoimmune destruction of the pancreatic beta cells.
Evidence of autoimmunity is provided by the appearance of au-
toantibodies prior to the onset of clinical disease. The clinical pre-
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sentation ranges from mild nonspecific symptoms or no symp-
toms to coma. Although type 1 diabetes usually develops before 30
years of age, it can occur at any age. At presentation, most patients
are thin and have experienced weight loss, polyuria, polydipsia,
fatigue, and diabetic ketoacidosis.
Type 2 diabetes mellitus
In type 2 diabetes mellitus, the actions and secretion of insulin
are impaired, as opposed to the absolute deficiency of insulin that
occurs with type 1 diabetes mellitus. Type 2 diabetes is charac-
terised by two major pathophysiologic defects: (1) insulin resis-
tance, which results in increased hepatic glucose production and
decreased peripheral glucose disposal, (2) impaired β-cell secre-
tory function (Kahn 1997). Insulin resistance is an impaired bio-
logical response to the effects of exogenous or endogenous insulin.
Insulin resistance in the hepatic and peripheral tissues, particu-
larly skeletal muscle, leads to unrestrained hepatic glucose produc-
tion and diminished insulin-stimulated peripheral glucose uptake
and utilization (DeFronzo 1992). Insulin secretion by the pancre-
atic beta cell is initially sufficient to compensate for insulin resis-
tance, thereby maintaining normal blood glucose levels. Hyper-
insulinaemia, which accompanies insulin resistance, can maintain
sufficiently normal glucose metabolism as long as pancreatic β-cell
function remains normal. However, in patients who may develop
type 2 diabetes, insulin secretion eventually fails, leading to hyper-
glycaemia and clinical diabetes (Warram 1990). Individuals with
type 2 diabetes may have few or no classic clinical symptoms (see
above) of hyperglycaemia (Ruige 1997). The difficulty in main-
taining metabolic control, for example measured by haemoglobin
A1c (HbA1c) over time may be related to several behavioral factors
(for example difficulties with healthy eating, exercise, medication
regimens) but primarily reflects the underlying progressive decline
in β-cell function (UKPDS-16 1995).
Type 2 diabetes has traditionally been treated in a stepwise
manner, starting with lifestyle modifications (Armour 2004;
Gimenez-Perez 2001; Moore 2005), exercise (Thomas 2001) and
later on pharmacotherapy with oral agents. Several classes of oral
agents are available for clinical use. These mainly include insulin
secretagogues, drugs that delay the absorption of carbohydrates
from the gastrointestinal tract, and insulin sensitizers. Over time,
many patients with type 2 diabetes will require insulin therapy
(Burt 2005;Misso 2005;Richter 2005;Roberts 2005;Royle 2003;
Siebenhofer 2004).
Insulin secretagogues: Currently, the sulphonylureas used are
mainly glibenclamide (glyburide), glipizide, chlorpropamide,
tolbutamide, and glimepiride. These drugs stimulate pancreatic
β-cell insulin secretion by binding to a sulphonylurea receptor
(Lindberg 2002). The short-acting non-sulphonylurea insulin sec-
retagogues are repaglinide and nateglinide (Black 2003). These are
newer agents that also stimulate insulin secretion by binding to
the sulphonylurea receptor.
Alpha-glucosidase inhibitors: Acarbose and miglitol are α-glucosi-
dase inhibitors. These drugs slow the absorption of carbohydrates,
reducing especially postprandial elevations in plasma glucose lev-
els. They do not significantly lower fasting plasma glucose levels
but cause a modest reduction in HbA1c (Van de Laar 2005).
Insulin sensitizers: Metformin belongs to the biguanides class
(Saenz 2005; Salpeter 2003). Itmight increase insulin sensitivity in
the liver by inhibiting hepatic gluconeogenesis and thereby reduc-
ing hepatic glucose production. Metformin also seems to increase
peripheral insulin sensitivity by enhancing glucose uptake in the
muscle. The thiazolidinediones consist of rosiglitazone and piogli-
tazone. These substances decrease insulin resistance in muscle and
adipose tissue by activating the peroxisome proliferator-activated
receptor γ (PPAR−γ ) which increases production of proteins in-
volved in glucose uptake. They also decrease hepatic glucose pro-
duction by improving hepatic insulin sensitivity (Meriden 2004).
Description of the intervention
Type 2 diabetes mellitus can be treated by non-pharmacological
(diet, exercise) and pharmacological means. Insulin, as the natural
hormone of the body, might be given as animal (mainly pork or
beef ) insulin (Richter 2005), genetically constructed ’human’ in-
sulin or as insulin-’analogues’ with a modified molecular structure
compared to human insulin (Roberts 2005; Siebenhofer 2004).
Insulin is currently administered by diabetic people in various
ways: Subcutaneous injections, insulin pumps (Misso 2005), and
maybe in future by inhalation (Burt 2005; Royle 2003). Oral an-
tidiabetic agents are most often used to treat type 2 diabetes mel-
litus in its initial stages if lifestyle modifications have failed. The
thiazolidinediones rosiglitazone and pioglitazone offer new oral
treatment options and affect many tissues and parts of the body.
In order to evaluate their effects not only on metabolic control
in type 2 diabetes mellitus but also on patient-oriented outcomes
like cardiovascular disease, longer-term studies of at least 24 weeks
continuous intake will be critically appraised in this review.
Adverse effects of the intervention
An increase in bodyweight has been associated with rosiglitazone.
Oedema, anaemia and congestive heart failure have been reported
in patients receiving rosiglitazone. The patients who appear to be
at greatest risk of peripheral oedema, fluid retention and weight
gain, congestive heart failure and pulmonary oedema related to
rosiglitazone are probably those who use insulin or have New York
Heart Association class II, III or IV cardiac status, left-ventricular
dysfunction or renal insufficiency. Some reports of visual impair-
ment in patients taking rosiglitazone were described (Colucciello
2005). Case reports of liver function abnormalities associated with
rosiglitazone were documented (Marcy 2004; Menees 2005; Su
2006).
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How the intervention might work
Because traditional agents have a limited impact on insulin resis-
tance and β-cell function, thiazolidinediones may be an appropri-
ate choice especially for combination therapy in patients achieving
poor glycaemic control with initial monotherapy. By improving
insulin sensitivity, thiazolidinediones may exert beneficial effects
on cardiovascular risk factors. The excess cardiovascular risk in
type 2 diabetes cannot be attributed to classic risk factors alone
(mainly hypertension, hypercholesterolaemia and smoking), but
if present, these risk factors are at least as important as in patients
without diabetes (Stamler 1993). One explanation for the bene-
ficial effects of thiazolidinediones is their unique mechanism of
action as selective and potent inhibitors of PPAR-γ . PPAR-γ re-
ceptors are present in many tissues like adipose, hepatic and skele-
tal muscle tissue and control insulin-responsive genes, which have
a wide-ranging influence. Thiazolidinediones appear to improve
markers of inflammation and fibrinolysis, exert beneficial effects
on vascular reactivity, improve the lipid profile and fat distribu-
tion, and decrease pancreatic β-cell injury.
Rosiglitazone is a member of the thiazolidinedione group which
also encompasses troglitazone (withdrawn due to hepatic toxicity)
and pioglitazone. It increases the sensitivity of skeletal muscle, liver
and adipose tissue to insulin without directly stimulating insulin
secretion from pancreatic ß-cells, thereby reducing plasma glucose
levels and endogenous glucose production (Wagstaff 2002). Dif-
ferences in the side chain on the main thiazolidine-structure in
comparison to pioglitazone are thought to be responsible for the
distinct bioavailability, metabolism and antihyperglycaemic po-
tency of rosiglitazone. Although rosiglitazone appears to be asso-
ciated with some effects that are not mediated by PPAR-γ (Yang
2001), binding of rosiglitazone to this receptor seems to be the
important component of its mechanism of action. Rosiglitazone
has several pharmacodynamic properties which could ameliorate
the increased risk of cardiovascular disease in type 2 diabetes mel-
litus. In clinical studies in patients with type 2 diabetes mellitus,
rosiglitazone has been associated with reductions in the levels of
small dense low density lipoprotein-cholesterol (LDL-C) - despite
overall increases in total LDL-C - and increases in the levels of
high density lipoprotein-cholesterol (HDL-C). Diastolic and sys-
tolic blood pressure are thought to be decreased after rosiglitazone
treatment. Some other surrogate parameters indicating especially
cardiovascular risk were reported to be positively influenced by
rosiglitazone therapy.
Why it is important to do this review
Diabetes has long been recognised as a strong, independent risk
factor for cardiovascular disease, a problem which accounts for ap-
proximately 70% of all mortality in people with diabetes (Laakso
1999). Prospective studies show that compared to their non-dia-
betic counterparts, the relative risk of cardiovascular mortality for
men with diabetes is two to three and for women with diabetes is
three to four (Manson 1991; Stamler 1993). The increased car-
diovascular risk associated with diabetes is reflected in the obser-
vation that middle-aged individuals with diabetes have mortality
and morbidity risks that are similar to non-diabetic individuals
who have already suffered a cardiovascular event (Haffner 1998).
Both epidemiological andprospective data have demonstrated that
treatment of hyperglycaemia in type 2 diabetes mellitus is effec-
tive in reducing the risk of microvascular disease (for example dia-
betic retinopathy) but is less potent in reducing that of myocardial
infarction, stroke and peripheral vascular disease. Treatment of
other cardiovascular risk factors, although by definition less preva-
lent than hyperglycaemia, appears to be more effective in prevent-
ing macrovascular disease than treatment of hyperglycaemia. The
University Group Diabetes Program (UGDP) study was the first
published long-term investigation of people with type 2 diabetes
indicating no reduction of cardiovascular endpoints through im-
proved metabolic control but raised cardiovascular mortality af-
ter tolbutamide treatment (UGDP 1982). The study of Ohkubo
et al. which included relatively lean Japanese patients with type
2 diabetes, was the first to demonstrate prevention of microvas-
cular complications by intensive glucose control in patients with
type 2 diabetes (Ohkubo 1995). This study did not address the
question of whether good glycaemic control retards the progres-
sion of macrovascular disease. The United Kingdom Prospective
Diabetes Study (UKPDS) tested mainly whether intensive glu-
cose control with either a sulphonylurea or insulin influences the
risk of micro- and macrovascular complications compared with
conventional treatment (UKPDS-33 1998). The 10-year results
of the UKPDS evaluated drug treatment in non obese and obese
participants with newly diagnosed type 2 diabetes who were re-
ferred to hospital clinics. Over 10 years, HbA1c was 7.0% in the
intensive group compared with 7.9% in the conventional group.
The 0.9% difference in HbA1c between the intensive and conven-
tional groups over 10 years was smaller than the 1.9% difference
(9.0% and 7.1%) in HbA1c in the Diabetes Control and Com-
plications Trial (DCCT). The DCCT studied younger patients
with type 1 diabetes and assessed the effects of intensive versus
conventional insulin therapy on the incidence of microvascular
complications of diabetes (retinopathy, nephropathy, neuropathy)
over a mean follow-up of 6.5 years (DCCT 1993). The risk of
retinopathy, for example, was statistically significant reduced by
intensive insulin therapy with a number needed to treat (NNT)
to benefit of six (six type 1 diabetic patients need to be treated by
intensive in comparison to conventional insulin therapy over 6.5
years to avoid one additional patient to develop diabetic retinopa-
thy). The UKPDS had a factorial design meaning that another
study investigating intensive versus regular blood pressure control
(HDS 1993; UKPDS-38 1998) was imbedded in the main study.
Intensive versus conventional glucose control did not result in a
statistically significant difference in diabetes related mortality or
macrovascular disease endpoints but reduced the relative risk in
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the ’any diabetes related aggregate endpoint’ (Freemantle 2003).
Most of this benefit was due to a reduction in microvascular end-
points including the incidence of retinal photocoagulation, which
was assessed by ophthalmologists independent of the study. In the
UKPDS, the NNT to prevent one patient developing any of the
single endpoints over 10 years was 20 (95% confidence interval
(CI) 10 to 500) patients (UKPDS-33 1998). In contrast to these
results, publication of the UKPDS-34, which focused on obese
patients with newly diagnosed type 2 diabetes, found several clin-
ically important differences in macrovascular disease endpoints
with 10 years of treatment with metformin (UKPDS-34 1998).
In particular, the absolute risk reduction for the aggregate end-
points was more than 10% and for overall mortality was 7%, giv-
ing NNTs of 10 and 14, respectively, over 10 years (McCormack
2003).
The UKPDS was criticised on several grounds especially empha-
sising hidden biases in interpreting the results of this randomised
controlled trial (Ewart 2001; McCormack 2003; Nathan 1998).
Stratton et al. in their UKPDS-35 publication are often cited, who
tried to determine the relation between exposure to glycaemia over
time and the risk of macrovascular or microvascular complica-
tions in the UKPDS patients (Stratton 2000). This publication is
an epidemiological re-interpretation of UKPDS data proclaiming
that with each 1% reduction in mean HbA1c , reductions in risk
of 21% for deaths related to diabetes and 14% for myocardial in-
farction could be observed. The RCT itself, though, did not show
significant differences in this respect. Moreover, the UKPDS-38,
investigating tight versus less tight blood pressure control with the
use of an angiotensin converting enzyme inhibitor captopril or a
β-blocker atenolol as main treatment, showed relative risk reduc-
tions (in the group assigned to tight control compared with that
assigned to less tight control) of 24% in diabetes related endpoints,
32% in deaths related to diabetes, 44% in strokes and 37% in
microvascular endpoints (UKPDS-38 1998). Due to the factorial
design of the UKPDS with two interventions (improvement in
metabolic and blood pressure control) aiming at the same out-
comes, a fair interpretation of the data needs investigation of the
interaction between the two main treatment strategies (McAlister
2003; Montgomery 2003). UKPDS data should be available to
the scientific public to evaluate, among other things, the impor-
tance of the individual contribution of improved glucose versus
blood pressure control in type 2 diabetes mellitus. Unfortunately,
until now this has not happened.
Therefore, any new compound in the treatment of type 2 dia-
betes mellitus, like rosiglitazone, should not only be evaluated
with regards to surrogate outcomes (for example reductions in
fasting plasma glucose or HbA1c) but information is urgently
needed for the influence of any antidiabetic agent especially on
cardiovascular endpoints, which is the greatest problem in the
therapy of type 2 diabetes mellitus. Quite a number of health
technology assessment reports, (narrative) reviews, systematic re-
views and meta-analyses analysed interventions with rosiglitazone
in diabetes (Bloomgarden 2005; Boucher 2002; Boucher 2003;
Chiquette 2004; Cox 2004; Czoski-Murray 2004; Kreider 2002;
Lebovitz 2002; Malinowski 2000; Mukhtar 2005; NICE 2000;
NICE 2003; NICE 2003b;Wagstaff 2002;Wellington 2005). All
of them either suffer from methodological problems like insuf-
ficient quality assessment of primary studies, focus on surrogate
outcomes or are out-of-date. This systematic review tries to collate
all available data from RCTs of rosiglitazone treatment and evalu-
ates howmany studies investigated patient-oriented outcomes like
mortality, cardiovascular endpoints, adverse events and health-re-
lated quality of life.
A Cochrane review on the effects of pioglitazone treatment has
already been published (Richter 2006). For changes to the pub-
lished protocol see Appendix 12.
As this review contributes to the ongoing critical appraisal of RCTs
investigating the risk-benefit ratio of thiazolidinedione use by the
German Institute for Quality and Efficiency in Health Care (’In-
stitut fuer Qualitaet undWirtschaftlichkeit im Gesundheitswesen
- IQWiG), additional data (for example raw data from pharma-
ceutical companies often provided to IQWiG) of relevance might
be included in further updates.
O B J E C T I V E S
To assess the effects of rosiglitazone in the treatment of type 2
diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Adult persons (18 years or older) with type 2 diabetes mellitus. To
be consistent with changes in classification and diagnostic criteria
of type 2 diabetes mellitus through the years, the diagnosis should
have been established using the standard criteria valid at the time
of the beginning of the trial (for example ADA 1997; ADA 1999;
WHO 1980; WHO 1985; WHO 1998). Ideally, diagnostic cri-
teria should have been described. If necessary, authors’ definition
of type 2 diabetes mellitus was used. It was planned to subject
diagnostic criteria to a sensitivity analysis.
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Types of interventions
Therapy with rosiglitazone for a minimum of 24 weeks. The fol-
lowing comparisons were acceptable for evaluation:
• rosiglitazone versus placebo;
• rosiglitazone versus another oral antidiabetic medication
(meglitinide analogues, metformin, pioglitazone,
sulphonylureas);
• rosiglitazone in combination with an oral antidiabetic
medication or insulin versus a combination of an oral
antidiabetic medication or insulin (agents and treatment schemes
had to be identical).
Excluded interventions
Combination therapies consisting of different compounds in the
treatment arms (for example rosiglitazone plus metformin versus
uptitration of metformin or rosiglitazone plus gliclazide versus gli-
clazide). Another Cochrane review will investigate rosiglitazone-
metformin combination therapies including different treatment
regimens of these compounds. Furthermore, dipeptidyl peptidase-
4 (DPP-4) inhibitors for type 2 diabetes mellitus are excluded,
since these are the topic of another Cochrane review (Richter
2007), as well as glucagon-like peptide analogues for type 2 dia-
betes mellitus (Cochrane review, Snaith 2007).
Types of outcome measures
Primary outcomes
• mortality (all-cause mortality; diabetes related mortality
(death from myocardial infarction, stroke, peripheral vascular
disease, renal disease, hyper- or hypoglycaemia or sudden death));
• morbidity (all-cause morbidity as well as diabetes and
cardiovascular related morbidity, for example angina pectoris,
myocardial infarction, stroke, peripheral vascular disease,
neuropathy, retinopathy, nephropathy, erectile dysfunction,
amputation);
• adverse events (for example hypoglycaemia, congestive
heart failure, oedema).
Secondary outcomes
• health-related quality of life (using a validated instrument);
• costs;
• metabolic control as measured by glycosylated haemoglobin
A1c (HbA1c).
Covariates, effect modifiers and confounders
• compliance;
• co-morbidities (for example myocardial infarction, stroke);
• co-medication (for example antihypertensive drugs,
aspirin);
• age.
Timing of outcome measurement
Outcomes were assessed in the medium (24 weeks to less than
12 months of treatment) and long term (12 months or more of
treatment).
Search methods for identification of studies
Electronic searches
We used the following sources for the identification of trials:
• The Cochrane Library (issue 1, 2007);
• MEDLINE - OVID interface (until April 2007);
• EMBASE - OVID interface (until April 2007).
We also searched databases of ongoing trials: Current Controlled
Trials (www.controlled-trials.com - with links to other databases
of ongoing trials).
The described search strategy (see for a detailed search strategy
Appendix 1) was used forMEDLINE. For use with EMBASE and
The Cochrane Library this strategy was slightly adapted.
Additional keywords of relevancewere not identifiedduring any of
the electronic or other searches. If this had been the case, electronic
search strategies would have been modified to incorporate these
terms. Studies published in any language were included.
Searching other resources
We tried to identify additional studies by searching the reference
lists of included trials and (systematic) reviews, meta-analyses and
health technology assessment reports identified.
Data collection and analysis
Selection of studies
To determine the studies to be assessed further, two authors (BR
in combination with all the other authors) independently scanned
the abstract or titles, or both sections of every record retrieved. All
potentially relevant articles were investigated as full text. Interrater
agreement for study selection was measured using the kappa statis-
tic (Cohen 1960).Where differences in opinion existed, they were
resolved by a third party (other authors). If resolving disagreement
was not possible, the article would have been added to those ’await-
ing assessment’ and authors would have been contacted for clar-
ification. An adapted QUOROM (quality of reporting of meta-
analyses) flow-chart of study selection is attached (Moher 1999).
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Dealing with duplicate publications
In the case of duplicate publications and companion papers of
a primary study, we tried to maximise yield of information by
simultaneous evaluation of all available data. In cases of doubt,
the original publication (usually but not always the oldest version)
obtained priority.
Data extraction and management
For studies that fulfilled inclusion criteria, two authors (BR in
combination with all the other authors) independently abstracted
relevant population and intervention characteristics using stan-
dard data extraction templates (for details see Characteristics of
included studies and Appendix 2 to Appendix 16) with any dis-
agreements to be resolved by discussion, or if required by a third
reviewer. The data extraction form was pilot tested prior to use
andmodified. Any relevantmissing information on the trial would
have been sought from the original author(s) of the article, if re-
quired.
Assessment of risk of bias in included studies
Two authors (BR in combination with all the other authors) as-
sessed each trial independently. Possible disagreement was resolved
by consensus, or with consultation of a third reviewer in case of
disagreement. We planned to explore the influence of individual
quality criteria in a sensitivity analysis (see under ’sensitivity analy-
ses’). Interrater agreement for key quality indicators (concealment
of allocation, blinding, attrition rates) was planned to be calculated
using the kappa statistic (Cohen 1960). In cases of disagreement,
the rest of the group was consulted and a judgement was made
based on consensus.
Measures of treatment effect
Dichotomous data
Dichotomous outcomes (for example stroke yes/no) were planned
to be expressed as odds ratios (OR) or relative risks (RR) with 95%
confidence intervals (CI).
Continuous data
Continuous outcomes (for examplemetabolic control asmeasured
by glycosylated haemoglobin A1c (HbA1c) were planned to be
expressed, if possible, as mean differences with 95% CI.
Time-to-event data
Time-to-event outcomes (for example time until death) were
planned to be expressed as hazard ratios (HR) with 95% CI.
Unit of analysis issues
Different units of analysis (for exampleOR and RR) were planned
to be subjected to a sensitivity analysis.
Dealing with missing data
Relevant missing data were planned to be obtained from authors.
Evaluation of important numerical data such as screened, eligi-
ble and randomised patients as well as intention-to-treat and per-
protocol population was carefully performed. Drop-outs, misses
to follow-up and withdrawn study participants were investigated.
Issues of last-observation-carried-forward (LOCF) were critically
appraised and compared to specification of primary outcome pa-
rameters and power calculation.
Assessment of heterogeneity
In the event of substantial clinical or methodological or statistical
heterogeneity, study results were not planned to be combined in a
meta-analysis. Heterogeneity was identified by visual inspection of
the forest plots, by using a standard χ2-test and a significance level
of α = 0.1, in view of the low power of such tests. Quantification
of heterogeneity was also examined with I2, ranging from 0%
to 100% including its 95% confidence interval (Higgins 2002).
I2 demonstrates the percentage of total variation across studies
due to heterogeneity and was used to judge the consistency of
evidence. I2 values of 50% and more indicate a substantial level
of heterogeneity (Higgins 2003). When heterogeneity was found,
we attempted to determine potential reasons for it by examining
individual study characteristics and those of subgroups of themain
body of evidence.
Assessment of reporting biases
Funnel plots were planned to be used in exploratory data analyses
to assess for the potential existence of small study bias. There are
a number of explanations for the asymmetry of a funnel plot,
including true heterogeneity of effect with respect to study size,
poor methodological design of small studies and publication bias
(Sterne 2001). Thus, this exploratory data tool may be misleading
(Lau 2006; Tang 2000; Thornton 2000) and we did not place
undue emphasis on this tool.
Data synthesis
Data were planned to be summarised statistically if they were
available, sufficiently similar and of sufficient quality. Statistical
analysis was planned to be performed according to the statisti-
cal guidelines referenced in the newest version of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2005).
Pooled results were planned to be analysed using primarily a fixed-
effect model. Meta-regression was planned to be performed using
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Stata/SE (version 8, Stata Corporation, Texas USA) to determine
whether various study-level characteristics (for example follow-up
interval, duration of the intervention, total attrition, year of publi-
cation) affected the between-group changes in primary outcomes.
We planned to examine interaction terms for all models.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were planned to be performed only if one of the
primary outcome parameters demonstrated statistically significant
differences between treatment groups. The following subgroup
analyses were planned:
• gender (female versus male);
• age (depending on data but especially older versus younger
patients);
• patients with or without co-morbidities (for example heart
attack, stroke, peripheral vascular disease);
• patients with or without co-medication (for example
antihypertensive drugs, statins, aspirin).
Subgroup analyses were planned to be mainly used to explore
clinical or methodological or statistical heterogeneity.
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on effect size:
• repeating the analysis excluding unpublished studies;
• repeating the analysis taking account of study quality, as
specified above;
• repeating the analysis excluding any very long or large
studies to establish how much they dominate the results;
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
The robustness of the results was also planned to be tested by
repeating the analysis using different measures of effects size (risk
difference, odds ratio etc.) and different statistical models (fixed
and random-effects models).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The initial search identified 6058 records with eight additional
publications from reference lists; from these, 40 full papers were
singled out for further examination. The other studies were ex-
cluded on the basis of their abstracts or titles because they were
not relevant to the question under study (see Figure 1 for details of
the amended QUOROM (quality of reporting of meta-analyses)
statement). After screening the full text of the selected papers, 32
publications describing 18 studies finally met the inclusion crite-
ria.
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Figure 1. QUOROM (quality of reporting of meta-analyses) flow-chart of study selection
Most studies of at least 24 weeks rosiglitazone treatment were
published in the years 2005 to 2007 (10 trials), with the first study
was published in 2001.
Assessment of publication bias inter-rater agreement
Inter-rater agreement for study selection, that is qualifying a study
as ’included’ or ’potentially relevant’ was 95%.
Included studies
For details see Characteristics of included studies.
Interventions
Comparisons
Ten of the 18 included publications investigated rosiglitazone
monotherapy versus another monotherapy (12 monotherapy
arms), eight publications evaluated the combination of rosiglita-
zone with another glucose-lowering intervention versus a compa-
rable combination.
Monotherapy
• Five study arms compared rosiglitazone to placebo.
• Three study arms investigated rosiglitazone versus
metformin, two versus glyburide and one each versus repaglinide
or pioglitazone.
Combination therapy
• Eight publications investigated rosiglitazone combination
therapy versus a similar combination with another compound.
• Two studies evaluated glimepiride and metformin
combination, and one glibenclamide plus metformin,
pioglitazone plus metformin or pioglitazone plus glimepiride,
respectively.
• Three publications reported on triple combination
comparisons (sulphonylurea or glimepiride plus metformin plus
insulin).
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Number of study centres
Number of study centres ranged between one and 488, the mul-
ticentre design was dominant with a median of 31 study cen-
tres. Seven trials involved a substantial number of more than 40
study centres (Garber 2006;Goldberg 2005;Hanefeld2007;Kahn
2006; Lebovitz 2001; Phillips 2001; Rosenstock 2006b ).
Country and location
Ten studies were performed in the USA and Canada , six in Eu-
rope, one in Latin America, and one in China, Korea an Taiwan,
respectively (summarising to more than 18 studies due to multi-
national designs).
Setting
Eight publications presented some details about the study setting,
like recruitment of participants.
Treatment before study
If stated, most studies specified that pharmacotherapy like sulpho-
nylureas, metformin or both were used by participants before en-
tering the study. In two studies participants were treated by diet,
exercise or both, only (Hällsten 2002; Kahn 2006).
Methods
Duration of the intervention
Median treatment duration lasted 26 weeks, the longest trial had
a median duration of four years (Kahn 2006).
Duration of follow-up
Treatment duration and follow-up were identical in all studies, no
post-intervention follow-up was reported.
Run-in period
Ten studies described run-in periods. These usually lasted four
weeks where previous antidiabetic medication was stopped, titra-
tion of newmedication started or a placebo intervention initiated.
Language of publication
All included studies were published in English.
Participants
Who participated
Study participants were mainly white individuals with type 2 di-
abetes mellitus, in two studies the entire cohort was pharmaco-
naive (that is, people treated with diet only - Hällsten 2002; Kahn
2006).
Inclusion criteria
Investigators specified various inclusion criteria, such as diet non-
responders, sulphonylureas or metformin, or both failures and
certain glycosylated haemoglobin A1c (HbA1c) levels.
Exclusion criteria
Investigators specified various exclusion criteria. Nine of 18 in-
cluded studies stipulated specific exclusion criteria for the severity
of congestive heart failure (NYHA (New York Heart Association)
classification): Seven studies mentioned NYHA class III or IV and
two studies NYHA I or above (including the biggest trial, the
ADOPT (A Diabetes Outcomes Progression Trial) study - Kahn
2006).
Diagnostic criteria
Twelve studies provided some details of diagnostic criteria for type
2 diabetes mellitus.
Co-morbidities
Only four studies presented data on co-morbidities (Goldberg
2005; Jung 2005; Stocker 2007; Sutton 2002 ).
Co-medications
Six of the 18 included studies reported co-medications, either glu-
cose-lowering drugs or medication for other disorders, or both
(Derosa 2004; Derosa 2006b; Jung 2005; Kahn 2006; Ko 2006;
Stocker 2007).
Outcomes
Primary outcomes
Most studies investigated HbA1c and lipid parameters (such as
total cholesterol, high-density and low-density lipoprotein choles-
terol, triglycerides) as primary endpoints.
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Secondary and additional outcomes
Most studies evaluated lipid parameters, fasting and non-fasting
plasma glucose, adverse events, insulin, HbA1c, C-peptide and
indicators for insulin resistance as secondary outcomes.
Missing data
For this version of the review no author was contacted for addi-
tional data. As this review contributes to the ongoing critical ap-
praisal of RCTs investigating the risk-benefit ratio of thiazolidine-
dione use by the German Institute for Quality and Efficiency in
Health Care (’Institut fuer Qualitaet und Wirtschaftlichkeit im
Gesundheitswesen - IQWiG), additional data (for example raw
data from pharmaceutical companies often provided to IQWiG)
of relevance might be included in further updates.
Excluded studies
Twenty-two publications had to be excluded after careful evalua-
tion of the full publication. Main reasons for exclusion were trial
duration of less than 24 weeks or non comparable treatment reg-
imens (for details see ’Characteristics of excluded studies’).
Risk of bias in included studies
For details on methodological quality of included studies see
Appendix 13 to Appendix 16.
Overview
All included trials were of a parallel study design. No crossover
studies or factorial trials fulfilling the inclusion criteria were de-
tected. Two of the 18 included studies primarily specified a non-
inferiority or equivalence design (Hanefeld 2007; Sutton 2002)
with both trials specifying a 95%confidence interval (CI) of equiv-
alence. The other studies investigated superiority or inferiority of
rosiglitazone versus comparator compounds.
Interrater agreement for the key quality indicators randomisation,
concealment of allocation and blinding was 95%.
Allocation
All included studies were randomised controlled clinical trials of
parallel design and randomised individuals. The method of ran-
domisation was somewhat specified in five studies (Derosa 2004;
Derosa 2006b; Goldberg 2005; Kahn 2006; Stocker 2007), four
studies specified a randomisation ratio other than 1:1, that is ran-
domisation numbers were a-priori not equal between rosiglitazone
and comparator drugs (Hanefeld 2007; Kahn 2006; Phillips 2001;
Raskin 2004).
Four studies particularized concealment of allocation (Derosa
2004; Derosa 2006a; Kahn 2006; Stocker 2007).
Blinding
Eleven studies had a double-blind, five studies an open-label design
and two publications (Jung 2005; Ovalle 2004) did not lay down
information on blinding. No publication reported checking of
blinding conditions.
Incomplete outcome data
Screened and randomised patients
Nine studies or 50% of publications reported numbers of screened
patients (Garber 2006; Goldberg 2005; Hanefeld 2007; Kahn
2006; Lebovitz 2001; Phillips 2001; Rosenstock 2006b; Stocker
2007; Yang 2002), ranging from 120 to 6676 screened patients
with a median of 643 participants.
Altogether approximately 3888 participants were randomised to
rosiglitazone treatment and 4544 to control therapy, summing up
to 8432 individuals taking part in the included studies. A single
study contributed 52% of randomised individuals (Kahn 2006).
Discontinuing participants and attrition rates
Six studies described discontinuing participants and provided
some details about the reasons for terminating the trial (Goldberg
2005;Hanefeld 2007; Ko 2006; Rosenstock 2006b; Stocker 2007;
Sutton 2002).
Discontinuation rates in the rosiglitazone arms varied between five
and 40% (between four and 44% in control groups), with five
studies reporting high drop-out rates above 20% (Hanefeld 2007;
Kahn 2006; Lebovitz 2001; Raskin 2004; Sutton 2002).
Discontinuation rates between intervention and control groups
were dissimilar in six studies (Garber 2006; Hanefeld 2007; Jung
2005;Rosenstock 2006b; Stocker 2007; Sutton2002). Five studies
did not report details on attrition rates.
Intention-to-treat and per-protocol analyses, missing data
Thirteen of the 18 included studies reported an intention-to-
treat analysis, three trials a per-protocol evaluation and two both
(Goldberg 2005; Sutton 2002). Intention-to-treat was clearly de-
fined in 11 studies.
Six studies used the last-observation-carried-forward (LOCF) im-
putation method formissing data (Hanefeld 2007; Lebovitz 2001;
Phillips 2001; Rosenstock 2006b; Sutton 2002). For example, a
study of 12 months duration could extrapolate missing glycosy-
lated haemoglobin A1c (HbA1c) values for randomised patients
and declare these as endpoints, if the first post-randomisation
HbA1c value (for example after three months) was available. Two
studies used other methods for imputation. A clear definition of
the LOCF population was provided by one study, only (Lebovitz
2001).
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Other potential sources of bias
Definition of primary endpoint and secondary endpoints
Ten studies clearly defined primary endpoints in association with
power calculations, mostly one outcome, with one study present-
ing more than one parameter (Derosa 2006b).
The number of secondary endpoints, if stated as such, varied be-
tween two and 16. The total number of detailed endpoints in the
included studies ranged from seven to 17 with a mean of seven
endpoints. Only four studies adjusted for multiple outcomes, re-
peated measurements, or both (Derosa 2004; Derosa 2006b; Ko
2006; Phillips 2001).
Power calculation
Seven studies showed details of power calculation, the calculated
number of participants per group ranged from40 to approximately
1394.
Compliance measures
Five of the 18 included studies tried to investigate patients’ com-
pliance with the recommended treatments (Derosa 2004; Derosa
2006a; Derosa 2006b; Hällsten 2002; Stocker 2007).
Funding
Ten studies reported commercial funding, six publications did not
indicate possible funding sources (Derosa 2004; Derosa 2006b;
Ko 2006; Lebovitz 2001; Phillips 2001; Sutton 2002).
Publication status
Sixteen studies were published in peer review journals, none was
circulated as a journal supplement.
Effects of interventions
Baseline characteristics
For details of baseline characteristics see Appendix 2, Appendix 3,
Appendix 4 and Appendix 5.
Six studies demonstrated clinically relevant differences between
intervention and control groups, for example gender ratio (Garber
2006; Kahn 2006; Ko 2006; Raskin 2004; Rosenstock 2006b;
Stocker 2007). More men then women participated in the studies,
in the rosiglitazone arms women’s involvement ranged between
25% and 57%.
The mean age of patients randomised to rosiglitazone treatment
encompassed 47 to 61 years. Studies in established type 2 diabetes
patients and providing disease information (N = 13 ) showed a
diabetes duration of four to 9 years. The main ethnic group par-
ticipating in the trials consisted of white people, a few studies in-
cluded other ethnic populations as well.
Pharmaco-naive patients usually constituted a minor part of the
study participants, but two studies exclusively investigated this
group (Hällsten 2002; Kahn 2006), including the largest trial (the
ADOPT (A Diabetes Outcomes Progression Trial) study - Kahn
2006).
Most study participants with type 2 diabetes mellitus were also
overweight or obese, themean bodymass indices (BMI) in patients
randomised to rosiglitazone therapy rangedbetween23.3 and 33.6
kg/m2 (mean BMI of 29 kg/m2).
Baseline metabolic control as measured by mean glycosylated hae-
moglobin A1c (HbA1c) varied in the rosiglitazone arms between
6.8% and 9.5%, with a mean of 8.8%.
Primary outcomes
For details of primary outcomes see Appendix 10.
Mortality
No study included mortality as a primary or secondary endpoint.
The ADOPT trial investigated rosiglitazone, metformin and gly-
buride (glibenclamide) as initial treatment for recently diagnosed
type 2 diabetes mellitus by means of a double-blind RCT involv-
ing more than 4000 patients (Kahn 2006). Eligible participants
were between 30 and 75 years, with fasting plasma glucose levels
between 126 to 180 mg/dl (7.0 to 10.0 mmol/L) and were treated
by life style management only. The primary outcome was the time
from randomisation to treatment failure. Treatment failure was
defined as confirmed hyperglycaemia, that is fasting plasma glu-
cose levels greater than 180 mg/dl on consecutive testing or ac-
cording to the decision of an independent adjudication commit-
tee. Median duration of treatment was 4.0 years for rosiglitazone
and metformin and 3.3 years for glyburide. At five years, when
around 20% of the original cohort was being followed, the re-
ported cumulative incidence of treatment failure was 15% in the
rosiglitazone group and 21%/34% in the metformin/glyburide
group, respectively. The meanHbA1c level at four years compared
to max. 2g/day metformin and max. 15 mg/day glyburide, was
0.1% and 0.4% less after max. 8 mg/day rosiglitazone therapy.
Attrition rates were high in the ADOPT study: 37%, 38% and
44% did not finish the study in the rosiglitazone, metformin and
glyburide groups. Mortality data were reported in Table 2 of the
publication (’Adverse events, laboratory assessment, concomitant
use of cardiovascular drugs, hospitalization, and death’): All-cause
mortality was 34/1456 (2.3%) in the rosiglitazone group, 31/1454
(2.1%) in the metformin group and 31/1441 (2.2%) in the gly-
buride group.
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Morbidity
No study included morbidity like diabetic complications as a pri-
mary or secondary endpoint. Eight studies made some statement
about the number of participants who died during the course of
the trial (Derosa 2004; Derosa 2006b; Goldberg 2005; Hällsten
2002; Hanefeld 2007; Kahn 2006; Stocker 2007; Yang 2002).
The ADOPT trial (Kahn 2006) reported some data in Table 2 of
the publication (’Adverse events, laboratory assessment, concomi-
tant use of cardiovascular drugs, hospitalization, and death’):
Hospitalisation for any cause was comparable between the rosigli-
tazone, metformin and glyburide groups (11.6%, 11.8% and
10.4% of patients, respectively).
Cardiovascular disease [no (%)] of serious / total events was in-
creased in the rosiglitazone compared to the glyburide group:
• rosiglitazone 49 (3.4) / 62 (4.3)
• metformin 46 (3.2) / 58 (4.0)
• glyburide 26 (1.8) / 41 (2.8)
Investigator reported total events [no (%)] of congestive heart
failure happened more often in the rosiglitazone compared to the
glyburide group:
• rosiglitazone 22/1456 (1.5)
• metformin 19/1454 (1.3)
• glyburide 9/1441 ( 0.6)
Peripheral vascular disease [no (%)] of serious / total events data
were as follows:
• rosiglitazone 7 (0.5) / 36 (2.5)
• metformin 6 (0.4) / 27 (1.9)
• glyburide 4 (0.3) / 31 (2.2)
Adverse events
For details of adverse events seeAppendix 6, Appendix 7, Appendix
8 and Appendix 9.
The percentage of overall adverse events was comparable between
the intervention and control groups, serious adverse events ap-
peared to happen somewhat more often after rosiglitazone treat-
ment (median of 6% versus 4% in the control groups). Median
discontinuation rate following rosiglitazone administration was
also higher than after control therapy (median of 7% versus 4%).
Three studies evaluated and reported a more pronounced (appar-
ently dose-related) decrease of haemoglobin after rosiglitazone in-
take in comparison to other active compounds or placebo. Hae-
moglobin reductions ranged between 0.5 and 1.0 g/dl.
Eleven studies evaluated body weight and observed an increase
up to 5.0 kg after rosiglitazone treatment, four studies described
changes in body mass index up to a rise of 1.5 kg/m2.
Seven of the 18 included studies showed data on hypoglycaemic
episodes: Compared to active monotherapy control rosiglitazone
treatment resulted in somewhat lower rates of hypoglycaemia, es-
pecially when compared to sulphonylureas. Severe hypoglycaemic
events were rarely reported.
Data on the specific adverse event “oedema” were available in nine
of 18 studies. Overall, 4739 participants provided information
on the occurrence of oedema. The total number of events was
287 in the rosiglitazone and 134 in the control groups. Pooling
of the nine studies by means of fixed-effect meta-analysis revealed
an odds ratio of 2.27 (95% confidence interval (CI) 1.83 to 2.81,
P < 0.00001). The test for heterogeneity indicated an I2-value of
53.4%. The use of a random-effects model resulted in an odds
ratio of 4.62 (95% CI 2.28 to 9.38, P < 0.00001). The robustness
of this result was tested by repeating the analysis using the risk ratio
as a different measure of effect size, demonstrating a relative risk
of 2.10 (95% CI 1.72 to 2.55) for the fixed-effect model. Since
oedema event rates in most studies were below 10%, application
of the odds ratio appeared to be the more valid parameter.
We repeated the analysis excluding the large ADOPT study which
had a weight of 89.4% in the fixed-effect model. The odds ratio
in the fixed-effect model now was 6.04 (95% CI 3.31 to 11.02,
P < 0.00001) and 6.79 (95% CI 3.76 to 12.25, P < 0.00001).
Heterogeneity decreased to an I2 of 0%. The point estimate for
the ADOPT study only was 1.76 (95% CI 1.39 to 2.22).
Furthermore, the ADOPT study provided additional data on frac-
ture rates:
Men [n] fractures(%)
• rosiglitazone 32 (3.95)
• metformin 29 (3.36)
• glyburide 28 (3.35)
Women [n] fractures(%)
Total
• rosiglitazone 60 (9.30)
• metformin 30 (5.08)
• glyburide 21 (3.47)
Lower limb
• rosiglitazone 36 (5.58)
• metformin 18 (3.05)
• glyburide 8 (1.32)
Upper limb
• rosiglitazone 22 (3.41)
• metformin 10 (1.69)
• glyburide 9 (1.49)
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Spinal
• rosiglitazone 1 (0.16)
• metformin 1 (0.17)
• glyburide 1 (0.17)
Secondary outcomes
For details of secondary outcomes see Appendix 11.
Health-related quality of life
No study investigated health-related quality of life.
Costs
Only one study reported some data on costs of rosiglitazone ther-
apy (Rosenstock 2006b). Rosiglitazone 8 mg/day plus 2 g/day
metformin plus sulphonylurea agents were compared to the com-
bination therapy 10 units/day insulin glargine plus 2 g/day met-
formin plus sulphonylurea agents. Overall, the estimatedmean to-
tal cost of glycaemic control over 24 weeks was $235 lower among
participants treated with insulin glargine ($1368) compared with
rosiglitazone ($1603).
Metabolic control as measured by glycosylated haemoglobin
A1c (HbA1c)
Active glucose-lowering compounds like metformin, gliben-
clamide, or glimepiride resulted in similar reductions of HbA1c
compared to rosiglitazone treatment.
Heterogeneity
Only adverse events (oedema) as one of our primary outcomes
could be subjected to meta-analysis. Heterogeneity as indicated by
I2 was 53.4% but could be significantly reduced after elimination
of the biggest trial by Kahn et al (Kahn 2006).
Subgroup analyses
Not performed due to lack of data.
Sensitivity analyses
Various sensitivity analyses did not change substantially the risk
estimates for development of oedema after rosiglitazone treatment.
Publication bias
Not performed due to insufficient amounts of data.
D I S C U S S I O N
Summary of main results
This systematic review shows that published studies of at least
24 weeks rosiglitazone treatment in people with type 2 diabetes
mellitus did not provide evidence that patient-oriented outcomes
like mortality, morbidity, adverse effects and health-related qual-
ity of life are positively influenced by this compound. Metabolic
control measured by glycosylated haemoglobin A1c (HbA1c) as a
surrogate endpoint did not demonstrate clinically significant dif-
ferences to other oral antidiabetic drugs. One study investigated
economic costs of rosiglitazone versus insulin glargine therapy in-
dicating lower costs of insulin glargine treatment. Occurrence of
oedema was approximately doubled.
New safety data
The insulin-sensitising thiazolidinediones pioglitazone and rosigli-
tazone act as potent inhibitors of the peroxisome-proliferator-ac-
tivator receptor (PPAR) γ . Several PPARs exist with different ex-
pressions in various tissues. Activation of PPAR-γ by thiazolidine-
diones may cause an increase in bone marrow adiposity and a de-
crease in osteoblastogenesis, resulting in reduced bone formation.
Several publications of animal and human data are available (Ali
2005; Grey 2007; Lazarenko 2007; Schwartz 2006a; Schwartz
2006b; Yaturu 2007). To our knowledge, the ADOPT (A Dia-
betesOutcomes ProgressionTrial) - Kahn 2006) studywas the first
randomised controlled clinical trial which demonstrated increased
rates of fractures in women. According to the pharmaceutical
company producing pioglitazone, a re-analysis of the PROactive
(Prospective Pioglitazone Clinical Trial In Macrovascular Events)
study (Dormandy 2005) showed that 44/870 (5.1%) fractures
were observed in pioglitazone treated female patients compared to
23/905 (2.5%) controls.
It is unclear why it took so long to analyse adverse events in an
appropriate way. Adverse reactions on fracture rates only showed
up in a “Note added in proof” in the New England Journal of
Medicine (Kahn 2006) and the PROactive study publication did
not mention this side effect at all (Dormandy 2005). For an ade-
quate analysis of possible adverse events of published and unpub-
lished data adverse events information should be freely available
to the public and researches alike which should pose no problems
with nowadays information technology.
Just before finishing this review a meta-analysis on the effect of
rosiglitazone on the risk of myocardial infarction and death from
cardiovascular causes was published (Nissen 2007). Nissen and
Wolski analysed 42 trials of rosiglitazone treatment with a study
duration of more than 24 weeks. They found in the rosiglitazone
group, as comparedwith the control group, a significant increase of
the odds ratio for myocardial infarction of 1.43 (95% confidence
interval (CI) 1.03 to 1.98, P = 0.03. The odds ratio for death from
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cardiovascular causes was 1.64 (95% CI 0.98 to 2.74, P = 0.06).
Consequently, the US Food and Drug Administration (FDA), the
European Medicines Agency (EMEA) and GlaxoSmithKline is-
sued statements and warnings with regards to this meta-analysis.
Using the data from Nissen and Wolski we performed another
meta-analysis of the myocardial infarction rates for type 2 diabetes
only, analysing all studies, rosiglitazone versus monotherapy and
rosiglitazone versus combination therapies (in the original publi-
cation several other conditions were included as well to investigate
the overall cardiovascular risk of rosiglitazone). So far and lim-
ited to the sparse data available, we could not confirm significant
differences in odds ratios of rosiglitazone versus controls. On the
other hand, all odds ratios (with the exception of the compara-
tor glyburide - three studies only) indicated an increased risk of
rosiglitazone treatment, albeit not a statistically significant differ-
ence.
Moreover, it is disturbing to hear that the manufacturer of rosigli-
tazone (Avandia) provided the FDA with a pooled analysis of 42
RCTs in which rosiglitazone was compared to either placebo or
other antidiabetic therapies in patients with type 2 diabetes. The
meta-analysis suggested that patients receiving short-term (most
studies were of six months duration) treatment with rosiglitazone
may have a 30% greater relative risk of heart attacks and other
heart-related adverse events than patients treated with placebo or
another antidiabetic therapy. Questions of timing of this infor-
mation and how it was circled arise. Ongoing trials using rosigli-
tazone (RECORD) may provide additional data but for a drug
which was approved in 1999, the delay in obtaining information
about the benefit-risk ratio is considerable.
The onemajor ongoing study (RECORD)which eventually could
contribute valuable information about the role of rosiglitazone
treatment in type 2 diabetes mellitus (for details see Characteristics
of ongoing studies).
In the FDA statement ’FDA issues safety alert on Avandia’ it is
mentioned that “... other published and unpublished data from
long-term clinical trials of Avandia, including an interim analy-
sis of data from the RECORD trial (a large, ongoing, random-
ized open label trial) and unpublished re analyses of data from
DREAM (a previously conducted placebo-controlled, random-
ized trial) provide contradictory evidence about the risks in pa-
tients treated with Avandia.” We do hope that the conduct, analy-
sis and interpretation of this trial will reflect high quality scientific
standards and will not resemble the dishonourable events which
accompanied the PROactive study (for more details, see Richter
2006).We agree with the commentators on theNissen andWolski
publication that current drug approval for antidiabetic medica-
tions and possibly all new drugs needs to be changed (Psaty 2007).
The benefit-risk ratio of rosiglitazone therapy in type 2 diabetes
mellitus needs urgent clarification.
Potential biases in the review process
We focused on a minimum duration of 24 weeks rosiglitazone
therapy in order to have a chance to detect clinically meaningful
differences in patient-oriented parameters. Theoretically, studies
of a shorter duration could demonstrate a significant impact on
these outcomes but this is highly unlikely, even with regards to
important adverse events.
Moreover, it was difficult to separate primary studies from com-
panion papers because the latter quite often did not identify them-
selves as an additional publication of a parent study; especially
authors Derosa et al did not reference multiple publications to
each other (for details see ’References of included studies’, primary
studies are marked by an asterisk).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review shows that published studies of at least
24 weeks rosiglitazone treatment in people with type 2 diabetes
mellitus did not provide evidence that patient-oriented outcomes
like mortality, morbidity, adverse effects and health-related qual-
ity of life are positively influenced by this compound. Metabolic
control measured by glycosylated haemoglobin A1c (HbA1c) as a
surrogate endpoint did not demonstrate clinically significant dif-
ferences to other oral antidiabetic drugs. Occurrence of oedema
was approximately doubled. New safety data on increased rates of
fractures and possibly the risk of myocardial infarction and cardio-
vascular disease should lead to a very cautious approach to rosigli-
tazone use. If possible, other antidiabetic medications should be
employed.
Implications for research
Patient-oriented endpoint studies are urgently needed for theman-
agement of type 2 diabetes mellitus. The use of proxy indicators
like metabolic control is not sufficient to approve drugs which
many patients have to take for the rest of their lives. It appears
questionable whether new studies with rosiglitazone will be ethical
given the fact that less dangerous therapeutic alternatives exist.
A C K N OW L E D G E M E N T S
We are grateful to Susan L Norris who kindly provided some
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Derosa 2004
Methods DURATION OF INTERVENTION: 12 months
DURATION OF FOLLOW-UP:
12 months
RUN-IN PERIOD: none LANGUAGE OF PUBLICATION: English
Participants WHO PARTCIPATED:
white patients with type 2 diabetes mellitus and metabolic syndrome
INCLUSION CRITERIA:
white patients of either sex and ages >=18 years; type 2 diabetes according to ADA criteria (duration >=6
months); poor glycaemic control (HbA1c >=7.5% or >=1 adverse effect with diet and oral hypoglycaemic
agents (e.g. SU or metformin) given up to the maximum tolerated dose; all patients also diagnosed with
metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III classification;
triglyceridaemia (TG >=150 mg/dl) and hypertension (WHO criteria BP >=130/>=85 mmHg); fasting
C-peptide level >1.0 ng/ml
EXCLUSION CRITERIA:
receiving glimepiride, history of ketoacidosis, unstable or rapidly progressive diabetic retinopathy,
nephropathy or neuropathy; impaired hepatic function, impaired renal function, severe anaemia; severe
cardiovascular disease (e.g. NYHA III or IV congestive heart failure or a history of myocardial infarction
or stroke) or cerebrovascular conditions within 6 months before enrolment; women who were pregnant
or breastfeeding or of childbearing potential and not taking adequate contraceptive precautions
DIAGNOSTIC CRITERIA:
ADA 2001
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
40.2% receiving antihypertensive drugs; no patient was receiving lipid-lowering or antiaggregant drugs
Interventions NUMBER OF STUDY CENTRES:
three
COUNTRY/ LOCATION:
Italy
SETTING:
unclear
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg once daily (before lunch); +fixed oral dose of glimepiride (4 mg/day divided into 2
doses; before breakfast and before dinner)
CONTROL (DOSE/DAY):
pioglitazone 15 mg once daily (before lunch); + fixed oral dose of glimepiride (4 mg/day divided into 2
doses; before breakfast and before dinner)
TREATMENT BEFORE STUDY:
52.9% poor glycaemic control with metformin; 31% with SUs; 16.1% with glyburide; 14.9% with
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Derosa 2004 (Continued)
gliclazide
TITRATION PERIOD:
none
Outcomes PRIMARY OUTCOMES:
changes in BMI, HbA1c, lipid profile, and lipoprotein variables were the primary efficacy variables SEC-
ONDARY OUTCOMES:
fasting and postprandial plasma glucose, insulin levels, insulin resistance (HOMA); blood pressure; adverse
events
Notes AIM OF STUDY:
to assess the differential effect on glucose and lipid variables of the combination of glimepiride plus
pioglitazone or rosiglitazone in patients with type 2 diabetes and the metabolic syndrome
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Derosa 2006a
Methods DURATION OF INTERVENTION:
12 months
DURATION OF FOLLOW-UP:
12 months
RUN-IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
Caucasian patients with type 2 diabetes and poor glycaemic control with diet or experiencing adverse
effects with diet and metformin, administered up to the maximum tolerated dose
INCLUSION CRITERIA:
patients aged >= 18 years of either sex if they had type 2 diabetes mellitus according to the ADA (duration
>= 6 months), and if they had poor glycaemic control
(HbA1c levels > 7.5%) or
experienced adverse effects with diet and metformin, administered up to the maximum tolerated
dose; all patients were diagnosed with metabolic syndrome according to the National Cholesterol
Education Program Adult Treatment Panel III classification and they presented with triglyceridaemia
(triglycerides >= 150 mg/dL) and hypertension according to WHO 1999 criteria (systolic/diastolic BP >=
130/ >= 85 mmHg); all patients had a fasting C-peptide level > 1.0 ng/mL and were overweight (BMI
25.0 - 28.1)
EXCLUSION CRITERIA:
history of ketoacidosis; unstable or rapidly progressive diabetic retinopathy, nephropathy, or neuropathy;
impaired hepatic function (defined as plasma aminotransferase and/or gamma-glutamyltransferase levels
higher than the upper limit of normal (ULN) for age and sex], impaired renal function (defined as
24Rosiglitazone for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Derosa 2006a (Continued)
serum creatinine levels higher than the ULN for age and sex) or severe anaemia; patients with serious
cardiovascular disease (e.g. NYHA class I-IV congestive heart failure or a history of myocardial infarction
or stroke) or cerebrovascular conditions within 6 months before study enrollment; women who were
pregnant, breastfeeding or of childbearing potential and not taking adequate contraceptive precautions
DIAGNOSTIC CRITERIA:
ADA 2001
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
3
COUNTRY/ LOCATION:
Italy
SETTING:
Department of Internal Medicine and Therapeutics, University of Pavia (Pavia, Italy); the ‘G. Descovich’
Atherosclerosis Study Center, ‘D. Campanacci’ Clinical Medicine and Applied Biotechnology Depart-
ment, University of Bologna (Bologna, Italy); the Diabetes Care Unit at S. Carlo Hospital of Milano
(Milano, Italy).
INTERVENTION (DOSE/DAY):
metformin (mean dose 2250 mg/day) + rosiglitazone 4 mg/day (o.d., before lunch)
CONTROL (DOSE/DAY):
metformin (mean dose 2250 mg/day) + pioglitazone 15 mg/day (15 mg o.d., before lunch)
TREATMENT BEFORE STUDY:
diet or diet and metformin, administered up to the maximum tolerated dose
TITRATION PERIOD:
all paitents received metformin beginning with a dose of 1500 mg/day and increasing up to 3000 mg/day,
self-administered for 12 months, this dose depended on the tolerance or glycaemic control of the patients
(mean dosage: 2250 ± 750 mg/day)
Outcomes PRIMARY OUTCOMES:
changes in BMI, HbA1c, lipid profile, lipoprotein variables
SECONDARY OUTCOMES:
(not stated)
“FPG, PPG and HOMA index
were also used to assess efficacy”
BMI, HbA1c, fasting and postprandial plasma glucose (FPG, PPG) and insulin levels; HOMA; lipid
profile; treatment tolerability
Notes AIM OF STUDY:
to assess the differential effect on glucose and lipid variables of the combination of metformin plus
pioglitazone or metformin plus rosiglitazone in patients with type 2 diabetes mellitus and metabolic
syndrome
Risk of bias
Item Authors’ judgement Description
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Derosa 2006a (Continued)
Allocation concealment? Yes A - Adequate
Derosa 2006b
Methods DURATION OF INTERVENTION:
12 months
DURATION OF FOLLOW-UP:
12 months
RUN-IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetic patients with inadequate control on diet and oral hypoglycaemic agents
INCLUSION CRITERIA:
patients with metabolic syndrome diagnosis according to National Cholesterol Education Program
(NCEP) (ATP III) classification and they presented at least three following components:
1. type 2 diabetes mellitus.
2. triglyceridemia >= 150 mg/dl.
3. Blood pressure >= 130/85 mmHg
type 2 diabetes mellitus, according to ADA criteria; all were required to have been diagnosed as being
diabetic for at least 6months anddidnot have adequate glycaemic control (as suggested byADAguidelines)
with diet and oral hypoglycaemic agents such as sulphonylureas or metformin, both to the maximum
tolerated dose; no patients were taking glimepiride or thiazolidinediones; all patients had a fasting C-
peptide level > 1.0 ng/ml; mean BMI of 25.3;
furthermore, patients were hypertensive according to the WHO 1999 criteria (systolic BP >= 130 mmHg
and diastolic BP >= 85mm Hg) and had triglyceridaemia >= 150 mg/dl
EXCLUSION CRITERIA:
history of ketoacidosis; unstable or rapidly progressive diabetic background retinopathy,
nephropathy (microalbuminuria, evaluated by proteinuria <300mg/24 h) or neuropathy (evaluated by
electromyography); impaired liver function (transaminases > 40 U/L), impaired kidney function (creati-
nine > 1.5mg/dl) or anaemia (Hb < 11.5 g/L); unstable cardiovascular conditions (e.g. NYHA class
III or IV congestive heart failure or a history ofmyocardial infarctionor stoke) or cerebrovascular conditions
within 6months of study enrolment; women who were pregnant, lactating, or of child-bearing potential
while not taking adequate contraceptive precautions
DIAGNOSTIC CRITERIA:
ADA 2001
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
at entry, 42 patients (44.2%) were taking antihypertensive drugs [16 participants, ACE-inhibitors (38.
1%); 12 participant, calcium antagonists (28.6%); 10 participants, AT II antagonists (23.8%) and four
patients, alpha1-antagonists (9.5%)]; no patients were taking lipid-lowering or antiaggregation drugs
Interventions NUMBER OF STUDY CENTRES:
2
COUNTRY/ LOCATION:
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Derosa 2006b (Continued)
Italy
SETTING:
Department of Internal Medicine and Therapeutics at University of Pavia, the G. Descovich Atherosclero-
sis Study Center, D. Campanacci Clinical Medicine and Applied Biotechnology Department at University
of Bologna
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg/day + metformin 1500 mg/day
CONTROL (DOSE/DAY):
glimepiride 2 mg/day+ metformin 1500 mg/day
TREATMENT BEFORE STUDY:
patients did not have adequate glycaemic control with diet and oral hypoglycaemic agents such as sulpho-
nylureas or metformin, both to the maximum tolerated dose
TITRATION PERIOD:
none
Outcomes PRIMARY OUTCOMES:
changes in BMI, HbA1c, lipid profile and lipoprotein parameters were the primary efficacy variables
SECONDARY OUTCOMES:
(not stated) height, weight, BMI, HbA1c, FPG, PPG, fasting plasma insulin; postprandial plasma insulin;
lipid profile and lipoprotein parameters; HOMA; adverse events
Notes AIM OF STUDY:
the aim of this study is to compare the metabolic changes induced by metformin associated to glimepiride
or rosiglitazone in type 2 diabetic patients
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Garber 2006
Methods DURATION OF INTERVENTION:
24 weeks
DURATION OF FOLLOW-UP:
24 weeks
RUN-IN PERIOD:
during the 1-week, open-label lead-in phase, patients maintained their prescreening dosage of >= 1500
mg/day metformin therapy; LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetes patients inadequately controlled on metformin monotherapy.
INCLUSION CRITERIA:
adults (age 20-78 years) with established type 2 diabetes requiring oral therapy; before screening, patients
were required to be on a stable dosage of metformin >= 1500 mg/day for >= 8 weeks, HbA1c levels >7.0
and <= 12.0% and BMI >= 23 and <= 45; only patients willing and able to perform self-blood glucose;
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Garber 2006 (Continued)
women of childbearing potential had to practise acceptable methods of birth control and to have negative
pregnancy test results within 72 h of study treatment
EXCLUSION CRITERIA:
marked polyuria and polydipsia with >10% weight loss; the use of any hypoglycaemic agent other than
metformin within 8 weeks before screening; anaemia [haemoglobin level: <12.5 g/dl (men) and <11.0 g/
dl (women)] and significantly abnormal
renal, cardiac or hepatic dysfunction or disease; pregnant or nursing women and patients with known
sensitivity to any study medications were excluded.
DIAGNOSTIC CRITERIA:
not stated
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
76
COUNTRY/ LOCATION:
USA
SETTING:
not stated
INTERVENTION (DOSE/DAY):
metformin 500 mg plus rosiglitazone 4 mg/day (initial daily dose 1000-2000 mg + 4 mg, depending on
previous treatment)
[mean final dose of metformin plus rosiglitazone was 1819 and 7.1 mg]
CONTROL (DOSE/DAY):
metformin-glibenclamide 500/2.5 mg/day (initial daily dose 1000/5 mg)
[mean final dose of metformin-glibenclamide tablets was 1509/7.6 mg]
TREATMENT BEFORE STUDY:
patients were required to be on a stable dosage of metformin >= 1500 mg/day for >= 8 weeks
TITRATION PERIOD:
patientswere randomly assigned to one of twodouble-blind treatments, according to the dose ofmetformin
during the lead-in phase:
patients receiving 1500 mg/day metformin before screening received metformin-glibenclamide 1000/5
mg/day (in divided doses) or metformin 1500 mg plus rosiglitazone 4 mg daily (in divided doses); those
previously receiving >1500 mg/day were randomly assigned to metformin-glibenclamide 1000/5 mg (in
divided doses) or metformin 2000 mg plus rosiglitazone 4 mg daily (in divided doses)
study medications were titrated based on mean daily glucose levels to achieve a therapeutic glycaemic
target
Outcomes PRIMARY OUTCOMES:
change in HbA1c from baseline to week 24 or the last prior blinded visit
SECONDARY OUTCOMES:
changes in body weight and changes in fructosamine, FPG,
2-h postprandial plasma glucose and fasting insulin levels from baseline to week 24 or the last prior
blinded visit; proportion of patients achieving therapeutic glycaemic response (HbA1c levels <7.0% and
FPG levels <7 mmol/L) at week 24 or the
last prior blinded visit; safety outcomes included adverse events, particularly hypoglycaemic symptoms;
standard haematology, serum chemistry and urinalysis
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Garber 2006 (Continued)
Notes AIM OF STUDY:
to compare the effects of two combination regimens, metformin-glibenclamide combination tablets versus
metformin plus rosiglitazone in patients inadequately controlled on metformin monotherapy
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Goldberg 2005
Methods DURATION OF INTERVENTION:
24 weeks
DURATION OF FOLLOW-UP:
24 weeks
RUN-IN PERIOD:
oral placebo; single-blind; 4 weeks LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
patients with type 2 diabetes mellitus who were treated with diet alone or oral monotherapy
INCLUSION CRITERIA:
men or women >= 35 years of age with a diagnosis of type 2 diabetes (WHO)with fasting triglyceride levels
>= 150 mg/dl and< 600 mg/dl and fasting LDL cholesterol levels < 130 mg/dl; fasting serum C-peptide
levels >= 1 ng/ml and HbA1c values >= 7 and <= 11% if naive to previous oral antihyperglycemic therapy
or HbA1c values >= 7 and <= 9.5% if previously treated with oral antihyperglycemic monotherapy.
EXCLUSION CRITERIA:
treatment within 60 days of screening with insulin, systemic glucocorticoid therapy; combination oral
antihyperglycemic therapy, any lipid-lowering agent, or any weight loss agent; known allergy to any thia-
zolidinedione; serum creatinine >= 176.8 µmol/dl (>= 2.0 mg/dl) or 2+ dipstick proteinuria at screening;
ALT or AST >= 1.5 times the upper limit of normal or significant clinical liver disease; hemoglobin <
10.5 g/dl (females) or < 11.5 g/dl (males) at screening; abnormal thyrotropin; functional NYHA class
III or IV, history of CVD, or heart surgery within 6 months of screening; receiving renal dialysis or
having renal transplant; current therapy for malignancy other than basal cell or squamous cell skin cancer;
known history of HIV infection; signs or symptoms of drug or alcohol abuse; any condition or situation
precluding adherence to and completion of the protocol. For female subjects, appropriate birth control
was required, and pregnancy, breast-feeding, or the intent to become pregnant during the study period
prohibited participation.
DIAGNOSTIC CRITERIA:
WHO
CO-MORBIDITIES:
control vs intervention:
- pre-existing CVD or previous myocardial infarction 8.4% vs 6.6%
CO-MEDICATIONS:
not stated
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Goldberg 2005 (Continued)
Interventions NUMBER OF STUDY CENTRES:
100 (USA 78)
COUNTRY/ LOCATION:
USA, Puerto Rico, Mexico, Colombia
SETTING:
not stated
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg daily for 12 weeks; thereafter 4 mg twice daily (8 mg/day) for 12 weeks
CONTROL (DOSE/DAY):
pioglitazone 30 mg daily for 12 weeks; thereafter 45 mg once daily for 12 weeks
TREATMENT BEFORE STUDY:
participants discontinued any current oral antihyperglycaemic treatment
drug naive (%) -
I1: 26.5, I2: 26.6, C: 28.5
prior monotherapy (%) -
I1: 68.7, I2: 65.7, C1: 63.9
prior combination therapy (%) -
TITRATION PERIOD
- pioglitazone: 30 mg daily for 12 weeks; thereafter 45 mg once daily for 12 weeks
- rosiglitazone: 4 mg daily for 12 weeks; thereafter 4 mg twice daily (8 mg/day) for 12 weeks
Outcomes PRIMARY OUTCOMES:
triglycerides change from baseline to the last observed value SECONDARY OUTCOMES:
total cholesterol; plasma glucose; free fatty acids; apolipoprotein B; total insulin; C-peptide; highly sensi-
tive C-reactive protein; plasminogen activator inhibitor-1 (PAI-1); HDL-C; LDL-C particle size and con-
centration; surrogates of insulin resistance and beta-cell function (HOMA); safety assessments including
adverse events, body weight, pedal oedema and hypoglycaemic episodes
Notes AIM OF STUDY:
to test the hypothesis that pioglitazone has greater triglyceride-lowering effects than rosiglitazone - com-
parison of maximally effective monotherapy doses of pioglitazone and rosiglitazone in patients with type
2 diabetes and dyslipidemia receiving no concomitant glucose-lowering or lipid-lowering therapies
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Hanefeld 2007
Methods DURATION OF INTERVENTION:
52 weeks
DURATION OF FOLLOW-UP:
52 weeks
RUN-IN PERIOD:
eligible patients on oral antidiabetic medication stopped treatment 2 weeks before starting a 4-week,
single-blind placebo run-in period
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
patients with type 2 diabetes
INCLUSION CRITERIA:
FPG = 7.0 - 15.0 mmol/L C-peptide >= 27 nmol/L; BMI = 22 - 38
EXCLUSION CRITERIA:
patients on insulin therapy or those with diabetic complications requiring treatment, heart failure NYHA
III/IV, or serious renal, hepatic (liver function tests > 2.5 times the upper limit of normal). haematologic
impairment or women of childbearing potential
DIAGNOSTIC CRITERIA:
see above
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
71
COUNTRY/ LOCATION:
8 European countries
SETTING:
not stated
INTERVENTION (DOSE/DAY):
rosiglitazone as two equal daily doses (i.e. 2 mg bid or 4 mg bid) + placebo
CONTROL (DOSE/DAY):
glibenclamide once daily + placebo
TREATMENT BEFORE STUDY:
patients on monotherapy, combination therapy or diet and exercise only
TITRATION PERIOD:
over the first 12 weeks of treatment, the glibenclamide dose was titrated in 2.5 mg increments (final dose
range = 2.5 - 15 mg) to achieve optimal glycaemic
control
a double-dummy system allowed “titration”
of rosiglitazone without a change of dose
concomitant medications with potential effects on glucose or lipid metabolism were kept at constant dose
throughout the study
Outcomes PRIMARY OUTCOMES:
difference between rosiglitazone 8 mg/day and glibenclamide treatment groups with respect to change
from baseline in HbA1c after 52 weeks of treatment
SECONDARY OUTCOMES:
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(not stated)
lipids, insulin resistance (HOMA), insulin, proinsulin, 32-33 split proinsulin, safety, adverse effects
Notes AIM OF STUDY:
to compare the efficacy, tolerability and safety of rosiglitazone with that of
glibenclamide as monotherapy for patientswith type 2 diabetes over a 12-month treatment period
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Hällsten 2002
Methods DURATION OF INTERVENTION:
26 weeks
DURATION OF FOLLOW-UP:
26 weeks
RUN-IN PERIOD:
4-weeks with written diet instructions
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
patients with newly diagnosed or diet-treated type 2 diabetes
INCLUSION CRITERIA:
patients with type 2 diabetes, as defined by the WHO criteria and no diabetes complications
EXCLUSION CRITERIA:
fasting plasma glucose value < 6.1 mmol/l or > 11.0 mmol/L after the run-in period; patients with
cardiovascular disease, blood pressure > 160/100 mm Hg, previous or present abnormal hepatic or renal
function, antidiabetic medication, anemia, or oral corticosteroid treatment
DIAGNOSTIC CRITERIA:
WHO 1998
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
not stated (1)
COUNTRY/ LOCATION:
Finland
SETTING:
the patients were recruited by advertisement and among clients of the occupational health service in
Turku, Finland
INTERVENTION (DOSE/DAY):
rosiglitazone 8 mg/day (4 mg b.i.d.)
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CONTROL (DOSE/DAY):
C1: metformin 2 g (1g b.i.d.)
C2: placebo
TREATMENT BEFORE STUDY:
none or diet only
TITRATION PERIOD:
rosiglitazone (2 mg b.i.d. for 2 weeks, thereafter 4 mg b.i.d.), metformin (500 mg b.i.d. for 2 weeks,
thereafter 1 g b.i.d.), or placebo
Outcomes PRIMARY OUTCOMES:
not stated (insulin- and exercise-stimulated skeletal muscle glucose uptake, measured by means of positron
emission tomography (PET) during euglycemic-hyperinsulinemic
clamp and one-legged exercise)
SECONDARY OUTCOMES:
(not stated)
FPG, insulin, HbA1c, body weight, blood pressure
Notes AIM OF STUDY:
to compare the effects of treatment with rosiglitazone and metformin on insulin- and exercise-stimulated
glucose uptake and perfusion in skeletal muscle tissue in patients with type 2 diabetes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Jung 2005
Methods DURATION OF INTERVENTION:
6 months
DURATION OF FOLLOW-UP:
6 months
RUN-IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
Koreans with type 2 diabetes mellitus who showed poor glycaemic control with glimepiride
INCLUSION CRITERIA:
aged 20-70 years; secondary treatment failure (HbA1c > 8% on glimepiride 4 mg/day or equivalent dose
of other sulfonylureas)
EXCLUSION CRITERIA:
no other severe illnesses including liver failure, renal failure, heart failure
DIAGNOSTIC CRITERIA:
not stated
CO-MORBIDITIES:
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retinopathy -
I: 3/14, C: 3/13
proteinuria -
I: 2/14, C: 3/13
coronary heart disease -
I: 2/14, C: 2/13
CO-MEDICATIONS
lipid-lowering agents -
I: 5/14, C: 3/13
Interventions NUMBER OF STUDY CENTRES:
1
COUNTRY/ LOCATION:
Korea
SETTING:
diabetes clinic of the Seoul National University Hospital
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg/day + glimepiride 4 mg/day
CONTROL (DOSE/DAY):
metformin 1000 mg/day + glimepiride 4 mg/day
TREATMENT BEFORE STUDY:
glimepiride 4 mg/day or equivalent dose of other sulfonylureas
TITRATION PERIOD:
none
Outcomes PRIMARY OUTCOMES:
not stated
(resistin)
SECONDARY OUTCOMES:
(not stated)
adiponectin, FPG, lipids, HbA1c, plasma insulin, plasma C-peptide
Notes AIM OF STUDY:
to see whether improving insulin resistance can modulate circulating resistin levels, the effects of two
different insulin sensitizers, rosiglitazone and metformin, on plasma resistin concentrations in Korean
participants with type 2 diabetes mellitus were investigated
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Kahn 2006
Methods DURATION OF INTERVENTION:
4.0 years (median)
DURATION OF FOLLOW-UP:
4.0 years (median)
RUN-IN PERIOD:
4 weeks, placebo + diet/exercise
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
people with recently diagnosed type 2 diabetes mellitus, treated with life style management only
INCLUSION CRITERIA:
eligible patients were between the ages of 30 and 75 years, with fasting plasma glucose levels ranging
from 126 to 180 mg per deciliter (7.0 to 10.0 mmol per liter) while their only treatment was lifestyle
management
EXCLUSION CRITERIA:
clinically significant hepatic disease, renal impairment, a history of lactic acidosis, unstable or severe angina,
known congestive heart failure (CHF, New York Heart Association class I, II, III, or IV), or uncontrolled
hypertension
DIAGNOSTIC CRITERIA:
“recently diagnosed (i.e., within 3 years)”
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
Antihypertensive therapy [no. (%)]:
I1: 744 (51.1)
C1: 737 (50.7)
C2: 753 (52.3)
Lipid-lowering therapy [no. (%)]
I1: 378 (26.0)
C1: 377 (25.9)
C2: 370 (25.7)
Interventions NUMBER OF STUDY CENTRES:
488
COUNTRY/ LOCATION:
United States, Canada, and 15 European countries
SETTING:
not stated
INTERVENTION (DOSE/DAY):
rosiglitazone (max 8 mg/day)
CONTROL (DOSE/DAY):
metformin (max 2g/day)
glyburide (max 15 mg/day)
TREATMENT BEFORE STUDY:
diet/exercise
TITRATION PERIOD:
patients received initial daily doses of 4 mg of rosiglitazone, 500 mg of metformin, or 2.5 mg of glyburide
for each drug, the dose was increased according to the protocol to the maximum daily effective dose (4
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mg of rosiglitazone twice daily, 1 g of metformin twice daily, and 7.5 mg of glyburide twice daily
a dose increase was required at each visit if the fasting plasma glucose level was 140 mg per deciliter or
more; a dose reduction was permitted if adverse events occurred
Outcomes PRIMARY OUTCOMES:
time from randomization to treatment failure, which was defined as confirmed hyperglycemia (fasting
plasma glucose level, >180mg/dl) on consecutive testing after at least 6weeks of treatment at themaximum-
dictated or maximum-tolerated dose
of the study drug
an independent adjudication
committee, whose members were unaware of assignments
to treatment groups, used prespecified criteria (available
at www.nejm.org) to determine whether the primary outcome
was reached in cases in which a confirmatory fasting plasma glucose level had not been obtained, a patient
had withdrawn because of an insufficient therapeutic effect, or an additional glucose lowering drug had
been administered before the
confirmation of hyperglycemia (according to a protocol
amendment adopted in February 2004)
the threshold of more than 180 mg per deciliter for confirmed hyperglycemia was selected to
represent unequivocal failure in the maintenance of adequate glycemic control without incurring undue
hyperglycemic symptoms; the threshold of a fasting plasma glucose level of more than
140 mg per deciliter for increasing the dose of a study drug reflected clinical guidelines at the time of
study design.
SECONDARY OUTCOMES:
time from randomization to a confirmed fasting plasma glucose level of more than 140 mg per deciliter
after at least 6 weeks of treatment at the
maximum-tolerated dose of a study drug (for patients who entered the study with a fasting plasma glucose
level of 140 mg per deciliter or less)
other prespecified outcomes were levels of fasting plasma
glucose and glycated hemoglobin, weight, and
measures of insulin sensitivity and beta-cell function, as determined by homeostasis model assessment
(HOMA 2) with the use of the HOMA calculator (www.dtu.ox.ac.uk)
Secondary endpoints according to the published study protocol (Diabetes Care 2002):
- glycaemic control
- insulin sensitivity
- beta-cell function
- cardiovascular risk markers
- renal function
- patient reported outcomes (quality of life)
- resource utilization (direct health care costs will be assessed as the number of emergency room visits,
number of unscheduled visits to the study physician’s office, number of hospitalizations, and length of
stay. Furthermore, indirect economic costs associated
with bed days (days when patients stay in bed for half a day or more) and restricted activity days (days
when patients reduce their usual activities, such as housework
or shopping) will be evaluated)
- safety parameters (including hypoglycaemia)
Notes AIM OF STUDY:
to evaluate the durability of glycemic control in
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patients receiving monotherapy with rosiglitazone, metformin or glyburide
zhe therapeutic goal was a fasting plasma glucose
level below 140 mg/dl (7.8 mmol/L).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Ko 2006
Methods DURATION OF INTERVENTION:
one year
DURATION OF FOLLOW-UP:
one year
RUN-IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
Chinese patients with type 2 diabetes and conventional oral antidiabetic drugs failure
INCLUSION CRITERIA:
OAD failure was defined as persistent hyperglycaemia with haemoglobin AIc (HbA1c) >= 8.5% for 6 mo
or longer despite continuous use of maximal doses of conventional OAD; maximum recommended doses
of various OADs were given as follows: glibenclamide 20 mg/d, gliclazide 320 mg/d, glipizide 20 mg/d,
and metformin 3 g/d
EXCLUSION CRITERIA:
uncontrolled hypertension
with sitting blood pressure (BP) >200/110 mm Hg and/or a history of myocardial
infarction, cerebrovascular accident, or uncontrolled congestive heart failure during the previous 6 mo,
or significant renal impairment (plasma creatinine concentration >= 150 mmol/L)
DIAGNOSTIC CRITERIA:
not stated
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
antihypertensive agents [no (%)]:
I1: 31 (55.3)
C1: 14 (25.0)
lipid-lowering agents [no (%)]:
I1: 5 (8.9)
C1: 2 (3.6)
Interventions NUMBER OF STUDY CENTRES:
1
COUNTRY/ LOCATION:
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Hong Kong, China
SETTING:
Diabetic Clinic and Diabetes Center at AH Nethersole Hospital, in Tai PO, Hong Kong.
INTERVENTION (DOSE/DAY):
rosiglitazone max 8 mg/d
CONTROL (DOSE/DAY):
bedtime isophane insulin
TREATMENT BEFORE STUDY:
OAD - original OAD and other medications remained the same throughout the study
patients who fulfilled the inclusion criteria were referred to dietitians and diabetic nursing specialists for
reinforcement of their dietary habits, drug compliance, and an understanding of OAD failure; those with
HbA1c >=8.5% three months after reinforcement were included
TITRATION PERIOD:
oral rosiglitazone was started at 2 mg/d, insulin was begun at a dose of 6 units administered at night; the
insulin dose was titrated 2 to 4 wk later by a diabetic nursing specialist with an increment of 2 to 4 units
according to tolerability of the insulin injection and fasting plasma glucose (PG) improvement
at 12, 24, 36, and 52 wk, all patients were seen for assessment of tolerability
and compliance with treatment, and for measurement of lipid, glycemic, and other biochemical indices;
insulin dosage was adjusted at each visit if this was deemed necessary, with the goal of achieving an
HbA1c concentration <7.5%; if the drug was tolerable to patients, rosiglitazone was also increased to the
maximum dose of 8 mg
daily, with the goal of reducing HhA1c to <7.5% without the occurrence of significant
hypoglycemia
Outcomes PRIMARY OUTCOMES:
not stated (differences in HbA1c)
SECONDARY OUTCOMES:
(not stated)
lipids, BMI, FPG, blood pressure
Notes AIM OF STUDY:
to evaluate the efficacy and tolerability of rosiglitazone in patients with secondary oral anti-diabetic drug
failure and to directly compare rosiglitazone with bedtime insulin
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Lebovitz 2001
Methods DURATION OF INTERVENTION:
26 weeks
DURATION OF FOLLOW-UP:
26 weeks
RUN-IN PERIOD:
4-week single blind placebo baseline period (instruction on a weight maintenance diet)
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
patients with type 2 diabetes whose hyperglycemia was inadequately controlled by diet or an oral antihy-
perglycemic agent
INCLUSION CRITERIA:
36-81 years old, patients with a diagnosis of type 2 diabetes (as defined by the NDDG) if they had FPG
between 7.8 -16.7 mmol/L, fasting plasma C-peptide level greater than 0.26 nmol/L, and a body mass
index (BMI) between 22-38 kg/m2 at screening
EXCLUSION CRITERIA:
patients with angina or cardiac insufficiency NYHA class III or IV; renal impairment (serum creatinine >
159mmol/L), hepatic disease (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase, or total bilirubin, > 2.5 times the upper limit of the reference range); history of diabetic
ketoacidosis, history of chronic insulin use, symptomatic diabetic neuropathy; a serious major illness that
would compromise their participation; women of childbearing potential
DIAGNOSTIC CRITERIA:
NDDG 1979
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
42
COUNTRY/ LOCATION:
USA
SETTING:
not stated
INTERVENTION (DOSE/DAY):
I1: rosiglitazone 4 mg/day
(2 mg twice daily)
I2: rosiglitazone 8 mg/day
(4 mg twice daily)
CONTROL (DOSE/DAY):
placebo
TREATMENT BEFORE STUDY:
diet or an oral antihyperglycemic agent
drug naive (%) -
I1: 26.5, I2: 26.6, C: 28.5
prior monotherapy (%) -
I1: 68.7, I2: 65.7, C1: 63.9
prior combination therapy (%) -
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TITRATION PERIOD:
screening period of up to 14 days (during which patients discontinued all antidiabetic medications); 4-
week run-in; 26 weeks treatment period
Outcomes PRIMARY OUTCOMES:
change in HbA1c from baseline to 26 weeks
SECONDARY OUTCOMES:
(not stated)
comparisons of rosiglitazone with placebo for changes from baseline to week 26 in FPG, C-peptide,
immunoreactive insulin, proinsulin, 32-33 split proinsulin, fructosamine, urinary albumin excretion as
determined by urinary albumin/creatinine ratio (ACR), and serum lipids; the proportions of patients who
had a reduction in HbA1c of more than 1 percentage point or a reduction in FPG of more than 1.67
mmol/L at week 26 compared with baseline; HOMA;
interimmedical histories, reports of adverse events, and standard laboratory assessments (including clinical
chemistry, hematology, and urinalysis) were obtained at each visit; ECGs
Notes AIM OF STUDY:
to assess the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes whose
hyperglycemia was inadequately controlled by diet or an oral antihyperglycemic agent
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Ovalle 2004
Methods DURATION OF INTERVENTION:
6 months
DURATION OF FOLLOW-UP:
6 months
RUN-IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
patients with type 2 diabetes inadequately controlled on a maximized oral antihyperglycemic double
regimen of glimepiride and metformin
INCLUSION CRITERIA:
not stated
EXCLUSION CRITERIA:
not stated
DIAGNOSTIC CRITERIA:
not stated
CO-MORBIDITIES:
not stated
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CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
1
COUNTRY/ LOCATION:
USA
SETTING:
University of Alabama (Birmingham, Alabama, USA)
INTERVENTION (DOSE/DAY):
rosiglitazone 8 mg + metformin/sulfonylurea
(administered once daily)
CONTROL (DOSE/DAY):
insulin injection of 70130 mixed human insulin (administered once daily before supper) + metformin/
sulfonylurea
TREATMENT BEFORE STUDY:
maximized oral antihyperglycemic double regimen of glimepiride and metformin
TITRATION PERIOD:
the dose of rosiglitazone was fixed, whereas the 70/30 insulin was started at 0.2 units/kg and adjusted to
achieve a FPG level of <= 120 mgldl without occurrence of severe or frequent hypoglycaemia
Outcomes PRIMARY OUTCOMES:
not stated (pancreatic beta-cell function)
SECONDARY OUTCOMES:
(not stated)
fasting glucose, serum insulin, proinsulin levels, intravenous glucose tolerance tests, glucagon stimulation
test for C-peptide, HOMA
Notes AIM OF STUDY:
to confirm that TZDs improve pancreatic beta-cell function independent of the improvement in glycaemic
control
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Phillips 2001
Methods DURATION OF INTERVENTION:
26 weeks
DURATION OF FOLLOW-UP:
26 weeks
RUN-IN PERIOD:
4-week placebo
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetes patients
INCLUSION CRITERIA:
age 40-80 years; BMI 22-38 kg/m2; type 2 diabetes as defined by the NDDG; FPG 7.8-16.7 mmol/L
(140-300 mg/dl), and fasting C-peptide >= 0.27 nmol/L (>= 0.8 ng/ml) at the time of screening
EXCLUSION CRITERIA:
clinically significant renal disease, NYHA class III-IV, coronary insufficiency or congestive heart failure,
symptomatic diabetic neuropathy, or elevations in total bilirubin, alkaline phosphatase, alanine
aminotransferase (ALT), or aspartate aminotransferase 2.5 times the upper limit
DIAGNOSTIC CRITERIA:
NDDG 1979
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
65
COUNTRY/ LOCATION:
USA
SETTING:
not stated
INTERVENTION (DOSE/DAY):
I1: rosiglitazone 4 mg/day (4mg o.d)
I2: rosiglitazone 4 mg/day (2 mg b.i.d.)
I3: rosiglitazone 8 mg/day (8 mg o.d.)
I4: rosiglitazone 8 mg/day (4 mg b.i.d.)
CONTROL (DOSE/DAY):
placebo
TREATMENT BEFORE STUDY:
oral antihyperglycaemic agents were discontinued at least 14 days before a 4-week placebo run-in period
diet only (%) -
I1: 22.1, I2: 24.7, I3: 29.3, I4: 25.1, C: 22.5
oral monotherapy (%) -
I1: 61.3, I2: 55.9, I3: 54.7, I4: 64.7, C: 61.8
oral combination therapy (%) -
I1: 16.6, I2: 19.4, I3: 16.0, I4: 10.2, C1: 15.6
TITRATION PERIOD:
none
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Outcomes PRIMARY OUTCOMES:
change in HbA1c from baseline (end of the 4-week placebo run-in period) after 26 weeks of treatment
SECONDARY OUTCOMES:
the change from baseline after 26 weeks of treatment in FPG, immunoreactive insulin, C-peptide, lipid
levels
Clinical chemistry, hematology, liver enzymes, and urinalysis; HOMA
Notes AIM OF STUDY:
to examine the efficacy of rosiglitazone in reducing HbA1c and to evaluate the
therapeutic equivalence of once-daily and twice-daily dosing regimens
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Raskin 2004
Methods DURATION OF INTERVENTION:
24 weeks
DURATION OF FOLLOW-UP:
24 weeks
RUN-IN PERIOD:
a screening visit was followed by a 2-week washout period (previous diabetes medication discontinued)
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetic patients who had shown treatment failure using sulphonylurea monotherapy or metformin
monotherapy
INCLUSION CRITERIA:
type 2 diabetes for at least 12 months, with HbA1c values > 7.0% and <= 12% during previous monother-
apy with sulphonylurea or metformin (at 50% or more of the maximal recommended dosages) for at least
3 months
EXCLUSION CRITERIA:
if being treated within the previous 3 months with any of the following agents: insulin, repaglinide,
thiazolidinediones, alpha-glucosidase inhibitors, or combination therapy with antidiabetic medications
DIAGNOSTIC CRITERIA:
not stated
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
not stated (multicentre)
COUNTRY/ LOCATION:
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USA
SETTING:
not stated
INTERVENTION (DOSE/DAY):
I1: rosiglitazone 8.0 mg/day (mean final dose)
I2: rosiglitazone 6.0 mg/day (mean final dose) + repaglinide 4.0 mg/day (mean final dose)
CONTROL (DOSE/DAY):
repaglinide 12 mg/day (mean final dose)
TREATMENT BEFORE STUDY:
previous monotherapy with sulphonylurea or metformin (at 50% or more of the maximal recommended
dosages) for at least 3 months:
previous SU/metformin (n/n/tot) -
I1: 30/32/62, I2: 81/46/127 ,
C: 40/23/63
TITRATION PERIOD:
12-week dose-adjustment period:
repaglinide monotherapy
was initiated at 0.5 mg per meal if HbA1c levels were <= 8%, and at 1 mg per meal for all other patients;
the initial dosage of rosiglitazone monotherapy was 2 mg b.i.d.;
repaglinide/rosiglitazone combination therapy was initiated at 0.5 mg or 1 mg repaglinide per meal
(adjusted according to HbA1c as above), plus 2 mg rosiglitazone b.i.d
all patients in groups treated with repaglinide (monotherapy or combination) could have dosage adjusted
up to a maximal dose of 4 mg per meal; the rosiglitazone dosage could be doubled in monotherapy or
combination therapy groups at week 12, up to a maximum dose not to exceed 4 mg b.i.d.; the dose-
adjustment period was followed by 12 additional
weeks of maintenance therapy
Outcomes PRIMARY OUTCOMES:
change in HbA1c values from baseline to the end of study treatment
SECONDARY OUTCOMES:
changes in FPG values;
alanine aminotransferase (ALT); lipids; adverse events and reports of hypoglycemic episodes
Notes AIM OF STUDY:
to investigate the therapeutic effects
of repaglinide combination therapy with rosiglitazone; the efficacy, safety, and tolerability of the combi-
nation were compared with those of monotherapy with either agent alone, in patients who had shown
treatment failure using sulphonylurea monotherapy or metformin monotherapy
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Methods DURATION OF INTERVENTION:
24 weeks
DURATION OF FOLLOW-UP:
24 weeks
RUN-IN PERIOD:
during the screening/titration phase, patients not on the maximum metformin dose were titrated to 2000
mg/day; patients on 1000 mg/day increased their dose to 1500 mg/day immediately and to 2000 mg/day
1 week later (or maximum tolerated dose), followed by a 2-week stabilization period; patients on 1500
mg/ day increased their dose to 2000 mg/day immediately followed by a 2-week stabilization period
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
insulin-naive patients with type 2 diabetes inadequately controlled on dual oral therapy with sulfonylurea
plus metformin
INCLUSION CRITERIA:
participants >= 18 years of age with type 2 diabetes (HbA1c >= 7.5 and <= 11%) and a BMI of > 25;
continuous oral hypoglycemic treatment using stable daily doses of >= 50% of the maximally labeled dose
of a sulfonylurea and at least 1000 mg metformin was required for >= 3 months before the screening
visit
EXCLUSION CRITERIA:
stroke, myocardial infarction, angina pectoris, coronary artery bypass graft, or percutaneous translumi-
nal coronary angioplasty within the previous 12 months; history of congestive heart failure; treatment
with nonselective beta-blockers; hypoglycemia unawareness; impaired renal function; active liver disease;
substance or alcohol abuse; malignancy; planned radiological examinations requiring administration of
contrasting agents
DIAGNOSTIC CRITERIA:
HbA1c >= 7.5 and <= 11%
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
42
COUNTRY/ LOCATION:
USA
SETTING:
not stated
INTERVENTION (DOSE/DAY):
>= 50% of maximal-dose sulfonylurea and metformin + rosiglitazone 4 mg/day (mean daily dose rosigli-
tazone
was 7.1 +- 1.7 mg)
CONTROL (DOSE/DAY):
>= 50% of maximal-dose sulfonylurea and metformin + insulin glargine 10 units/day (mean daily dose
of insulin
glargine was 38.5 +- 26.5 IU)
TREATMENT BEFORE STUDY:
slfonylurea and metformin doses remained unchanged during the treatment phase of the study
TITRATION PERIOD:
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(see run-in phase)
all patients randomized to insulin glargine received a single daily subcutaneous injection at bedtime at
a starting dose of 10 IU/day for 7days, the dose was titrated weekly according to self-monitored FPG,
supervised centrally to ensure compliance, to meet target FPG <100 -120 mg/dl (<5.5- 6.7 mmol/L)
all patients randomized to treatment with rosiglitazone received a starting oral dose of 4 mg once daily
for 6 weeks; if the FPG value was >100 mg/dl (>5.5 mmol/L) after 6 weeks, rosiglitazone was increased
to a maximum of 8 mg/day
Outcomes PRIMARY OUTCOMES:
not stated (HbA1c differences between therapies)
SECONDARY OUTCOMES:
(not stated)
assessment of hypoglycaemia profile; changes in FPG, body weight, and serum lipids; proportion of
patients achieving HbAA1C <= 7%; cost of therapy
safety was assessed in the intent to treat (ITT) population through adverse events, hypoglycaemia, body
weight, physical examinations, vital signs, standard hematology,and blood chemistry
a physical examination to identify signs of peripheral oedema was performed at baseline and final visit or
at patient discontinuation
Cost analysis:
The economic costs of glyceemic control were compared by combining selected measures of resource use
with unit-cost estimates. Resource measures included study medication, other antihyperglycaemic agents,
syringes for insulin glargine,
glucose testing supplies for both groups, and recommended liver function tests for the rosiglitazone group.
Resource use was
based on trial data over the 24-week period. Costs of medications, insulin syringes, test strips, and lancets
were
estimated using average wholesale prices expressed in 2002 U.S. dollars and were based on the numbers
actually dispensed. The cost of hepatic function panels was estimated using fee schedules under Medi-
care’s Resource-Based Relative Value Scale. Economic costs were summarized using means and 95% CIs
and calculated through techniques of bootstrapping. Results were not adjusted for differences between
treatment
Notes AIM OF STUDY:
to evaluate the efficacy and safety of insulin glargine or rosiglitazone as add-on therapy in patients with type
2 diabetes with chronic hyperglycemic control despite maximized combination therapy with metformin
plus a sulfonylurea
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Stocker 2007
Methods DURATION OF INTERVENTION:
24 weeks
DURATION OF FOLLOW-UP:
24 weeks
RUN-IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetes patients with suboptimally controlled diabetes mellitus
INCLUSION CRITERIA:
between 21 and 80 years of age, with a glycosylated hemoglobin level above 7.0% during treatment with
either diet modification or sulfonylurea monotherapy
EXCLUSION CRITERIA:
known inflammatory diseases (including inflammatory bowel disease, vasculitis, and rheumatologic
disease), insulin use, corticosteroid use, an infection within 1 month of enrollment, glomerular filtration
rate < 60 ml/min,
pregnancy, known history of myocardial infarction or congestive heart failure, secondary diabetes (includ-
ing Cushing’s syndrome and acromegaly), hypersensitivity to metformin or rosiglitazone, or a history of
carotid endarterectomy DIAGNOSTIC CRITERIA:
not stated
CO-MORBIDITIES:
known cardiovascular disease [no (%)]
I1: 2 (4.4%)
C1: 3 (6.4%)
CO-MEDICATIONS:
statin use [no (%)]:
I1: 24 (53.3%)
C1: 23 (48.9%)
aspirin use [no (%)] :
I1: 21 (46.7%)
C1: 28 (59.6%)
beta-blocker use [no (%)]:
I1: 8 (17.8%)
C1: 7 (14.9%)
calcium-channel
blocker use [no (%)]:
I1: 6 (13.3%)
C1: 13 (27.7%)
angiotensin receptor
blocker use [no (%)]:
I1: 2 (4.4%)
C1: 0 (0%)
ACE inhibitor use [no (%)]:
I1: 23 (51.1%)
C1: 30 (63.8%)
sulfonylurea use [no (%)]:
I1: 34 (75.6%)
C1: 34 (72.3%)
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Stocker 2007 (Continued)
Interventions NUMBER OF STUDY CENTRES:
1
COUNTRY/ LOCATION:
USA
SETTING:
Diabetes Institute of theWalter Reed Army Medical Center, Washington DC, USA
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg o.d.
CONTROL (DOSE/DAY):
metformin 850 mg b.i.d.
TREATMENT BEFORE STUDY:
diet modification or sulfonylurea monotherapy
TITRATION PERIOD:
other concurrent therapies (sulfonylurea, antihypertensive, or
statin medications) were continued at stable doses during the study
nutrition counseling and diabetes education was offered to all participants at enrollment, in addition to
their study medication
Outcomes PRIMARY OUTCOMES:
change in C-reactive protein (CRP) levels after 24 weeks between the metformin and rosiglitazone treat-
ment groups
SECONDARY OUTCOMES:
the predefined secondary
end point was the change in mean and maximal CIMT of the common carotid artery
further outcomes:
FPG, HbA1c, lipids, weight, carotid intima media thickness (CIMT)
Notes AIM OF STUDY:
to compare the effects of rosiglitazone and metformin on C-reactive
protein (CRP) and carotid intima media thickness (CIMT)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Sutton 2002
Methods DURATION OF INTERVENTION:
52 weeks
DURATION OF FOLLOW-UP:
52 weeks
RUN-IN PERIOD:
4-week placebo run-in period (single-blind, with diet maintenance)
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetic patients
INCLUSION CRITERIA:
patients aged 40-80 years were eligible if they met the NDDG definition forvtype 2 diabetes, with en-
dogenous insulin production (fasting C-peptide concentration >= 0.8 ng/ml at screening); female patients
had to be postmenopausal, surgically sterile, or currently using hormonal contraceptives or intrauterine
devices
EXCLUSION CRITERIA:
clinically significant renal disease (serum creatinine level >= 1.8mg/dl) or hepatic disease (alanine transam-
inase, aspartate transaminase, total bilirubin, or alkaline phosphatase levels > 2.5 times the upper limit of
the normal laboratory range); previous treatment for myocardial infarction; NYHA class III-IV, coronary
insufficiency or congestive heart failure; previous or existing treatment with ACE inhibitors, angiotensin
II receptor antagonists, beta-blockers, or calcium-channel blockers; echocardiographic evidence of marked
left ventricular hypertrophy at baseline; or uncontrolled BP (>160/>100 mmHg); whereas patients taking
diuretics and lipid-lowering agents were not excluded from the study, doses were not to be changed during
the study unless deemed medically appropriate
DIAGNOSTIC CRITERIA:
NDDG
CO-MORBIDITIES:
concomitant hypertension (%) - I: 7.7, C: 7.0
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
19
COUNTRY/ LOCATION:
USA
SETTING:
not stated
INTERVENTION (DOSE/DAY):
rosiglitazone 8 mg (4 mg b.i.d.)
CONTROL (DOSE/DAY):
glyburide
TREATMENT BEFORE STUDY:
previous antidiabetic treatment :
diet only (%) - I: 21.2, C: 18.2
single agent (%) - I: 70.2, C: 69.7
combination therapy (%): I: 8.7, C: 12.1
2-week screening period; previous oral antidiabetic medications were discontinued at the screening visit,
at which time all patients received placebo and dietary instruction; patients were reevaluated at 2-week
intervals during the placebo run-in period; those with FPG >= 140 mg/dl but <= 300 mg/dl at visits 2
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Sutton 2002 (Continued)
and 3 were eligible to enter the treatment period
TITRATION PERIOD:
glyburide (q.i.d. or b.i.d.) was titrated at the discretion of the investigator to optimal glycemic effect over
the first 8 weeks and then held constant for the duration of the study period; the dose of glyburide did
not exceed 20 mg/day
Outcomes PRIMARY OUTCOMES:
change frombaseline in left ventricularmass index, at weeks 28 and 52, with the between-groups difference
as the primary comparison of interest
SECONDARY OUTCOMES:
(not stated)
changes from baseline to weeks 28 and 52 in left ventricular end-diastolic volume and ejection fraction
as well as mean values of BP, heart rate, arterial pressure, and pulse pressure (from 24-h ambulatory
monitoring); glycemic control (HbA1c and FPG); serum lipids fasting clinical laboratory tests, including
chemistry, haematology, and urinalysis
clinical interpretation of safety was based on review of ECG and echocardiographic data, adverse event
reports, and laboratory values
Notes AIM OF STUDY:
to assess the effect of long-term rosiglitazone treatment on cardiac structure/function and glycaemic control
in patients with type 2 diabetes compared with glyburide
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Yang 2002
Methods DURATION OF INTERVENTION:
6 months
DURATION OF FOLLOW-UP:
6 months
RUN-IN PERIOD:
single-blind placebo/sulfonylurea run-in period for 4 weeks to establish baseline characteristics
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED:
type 2 diabetic patients on concurrent sulphonylurea therapy
INCLUSION CRITERIA:
aged 30-80 years; type 2 diabetic patients according to diagnostic criteria of theWHO, FPG 7-15 mmol/
L and HbA1c > 7.5%; who had been stable on sulfonylurea therapy for at least 2 months before the
screening
EXCLUSION CRITERIA:
other severe medical problems and severe microvascular complications requiring immediate medical at-
tention
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Yang 2002 (Continued)
DIAGNOSTIC CRITERIA:
WHO
CO-MORBIDITIES:
not stated
CO-MEDICATIONS:
not stated
Interventions NUMBER OF STUDY CENTRES:
not stated (1)
COUNTRY/ LOCATION:
Taiwan
SETTING:
not stated
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg/day (2mg b.i.d.) + sulfonylureas
CONTROL (DOSE/DAY):
placebo (twice daily) + sulfonylureas
TREATMENT BEFORE STUDY:
who had been stable on sulfonylurea therapy for at least 2 months before the screening
TITRATION PERIOD:
Outcomes PRIMARY OUTCOMES:
not stated (plasma levels of adiponectin)
SECONDARY OUTCOMES:
(not stated)
HbA1c; body weight, height, blood pressure, heart rate, plasma glucose, total cholesterol, triglycerides,
HOMA
Notes AIM OF STUDY:
to assess whether adiponectin levels might increase in type 2 diabetes patients treated with rosiglitazone
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
ACE = angiotensin converting enzyme; ADA = American Diabetes Association; ALT = alanine aminotransferase; AST = aspartate
aminotransferase; AT II = angiotensin II; b.(i.)d. = bis in die, twice daily; BMI = body mass index (kg/m2); BP = blood pressure;
C = control group; CRP = C-reactive protein; CVD = cardiovascular disease; ECG = electrocardiogram; FCBG = fasting capillary
blood glucose; FPG = fasting plasma glucose; HbA1c = glycosylated haemoglobin A1c; HOMA = homeostasis model assessment
(of insulin sensitvity); I = intervention group; ITT = intention-to-treat; NDDG = National Diabetes Data Group; NYHA = New
York Heart Association; OAD = oral antidiabetic drug: OAM = oral antidiabetic medication; o.d. = once daily; PPAR = peroxisome
proliferator activated receptor; PPG = postprandial glucose; q.d. = quaque die, once a day; SU = sulfonylureas; t.i.d. = ter in die,
three times daily; TZD = thiazolidinediones (“glitazones”); U = Unit; WHO = World Health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bailey 2005 treatment regimens not comparable (rosiglitazone plus metformin versus metformin)
Baksi 2004 treatment regimens not comparable (rosiglitazone plus gliclazide versus gliclazide)
Barnett 2003 treatment regimens not comparable (rosiglitazone plus sulfonylureas versus sulfonylureas plus placebo)
Dailey 2004 treatment regimens not comparable (rosiglitazone plus glyburide/metformin versus placebo plus glyburide/
metformin)
Fonseca 2000 treatment regimens not comparable (rosiglitazone plus metformin versus placebo plus metformin)
Fonseca 2003 treatment regimens not comparable (rosiglitazone plus placebo versus rosiglitazone plus nateglinide)
Gomez-Perez 2002 treatment regimens not comparable (rosiglitazone plus metformin versus placebo plus metformin)
Hubacek 2004 rosiglitazone treatment less than 24 weeks
Kerenyi 2004 treatment regimens not comparable (rosiglitazone plus glibenclamide versus glibenclamide)
McCluskey 2004 treatment regimens not comparable (rosiglitazone plus glimepiride versus glimepiride)
Negro 2005 treatment regimens not comparable (rosiglitazone plus metformin versus placebo plus metformin)
Raskin 2001 treatment regimens not comparable (rosiglitazone plus insulin versus placebo plus insulin)
Reynolds 2002 treatment regimens not comparable (rosiglitazone plus insulin plus life-style modification versus placebo plus
insulin plus life-style modification)
Rosenstock 2006a treatment regimens not comparable (rosiglitazone plus glipizide versus placebo plus glipizide)
Tan 2005a rosiglitazone treatment less than 24 weeks
Tan 2005b rosiglitazone treatment less than 24 weeks
Vongthavaravat 2002 treatment regimens not comparable (rosiglitazone plus sulfonylureas versus sulfonylureas alone)
Wang 2005 treatment regimens not comparable (rosiglitazone versus “control” without treatment)
Weissman 2005 treatment regimens not comparable (rosiglitazone plus metformin versus metformin)
Wolffenbuttel 2000 treatment regimens not comparable (rosiglitazone plus sulfonylureas versus sulfonylureas plus placebo)
Wong 2005 treatment regimens not comparable (rosiglitazone plus insulin versus insulin)
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Zhu 2003 treatment regimens not comparable (rosiglitazone plus sulfonylureas versus sulfonylureas plus placebo)
Characteristics of ongoing studies [ordered by study ID]
RECORD
Trial name or title Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD)
Methods
Participants RECORD is a 6-year, randomised, open-label study in
type 2 diabetic patients with inadequate blood glucose control (HbA1c 7.1-9.0%) on metformin or sulpho-
nylurea alone
Interventions after a 4-week run-in, participants are randomised by current treatment stratum to
add-on rosiglitazone, metformin or sulphonylurea, with
dose titration to a target HbA1c of <=7.0%; if confirmed HbA1c rises to >= 8.5%, either a third glucose-
lowering drug
is added (rosiglitazone-treated group) or insulin is started
(non-rosiglitazone group); the same criterion for failure of triple oral drug therapy in the rosiglitazone-treated
group is used for starting insulin in this group
Outcomes the primary endpoint is the time to first cardiovascular hospitalisation or death, blindly adjudicated by a
central endpoints committee; the
study aim is to evaluate non-inferiority of the rosiglitazone
group versus the non-rosiglitazone group with respect to cardiovascular outcomes; safety, tolerability and
study conduct are monitored by an independent board
Starting date recruitment began in April 2001 and was completed in April 2003
Contact information P. D. Home
School of Clinical Medical Sciences-Diabetes,
University of Newcastle upon Tyne,
Medical School, Framlington Place,
Newcastle upon Tyne,
NE2 4HH, UK
E-mail: philip.home@newcastle.ac.uk
Tel.: +44-191-2227019
Fax: +44-191-2220723
Notes study design and protocol published in Diabetologia 2005;48: 1726-35
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D A T A A N D A N A L Y S E S
Comparison 1. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. of patients experiencing
oedema
9 4739 Odds Ratio (M-H, Fixed, 95% CI) 2.27 [1.83, 2.81]
Analysis 1.1. Comparison 1 Adverse events, Outcome 1 No. of patients experiencing oedema.
Review: Rosiglitazone for type 2 diabetes mellitus
Comparison: 1 Adverse events
Outcome: 1 No. of patients experiencing oedema
Study or subgroup Rosiglitazone Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hanefeld 2007 18/200 4/207 3.0 % 5.02 [ 1.67, 15.10 ]
Kahn 2006 205/1456 123/1441 89.8 % 1.76 [ 1.39, 2.22 ]
Ko 2006 2/56 0/56 0.4 % 5.18 [ 0.24, 110.45 ]
Lebovitz 2001 18/169 3/158 2.3 % 6.16 [ 1.78, 21.34 ]
Phillips 2001 13/187 3/173 2.5 % 4.23 [ 1.19, 15.12 ]
Raskin 2004 2/62 0/63 0.4 % 5.25 [ 0.25, 111.56 ]
Rosenstock 2006b 14/112 0/104 0.4 % 30.77 [ 1.81, 522.71 ]
Stocker 2007 8/45 0/47 0.3 % 21.53 [ 1.20, 385.19 ]
Sutton 2002 7/104 1/99 0.8 % 7.07 [ 0.85, 58.57 ]
Total (95% CI) 2391 2348 100.0 % 2.27 [ 1.83, 2.81 ]
Total events: 287 (Rosiglitazone), 134 (Control)
Heterogeneity: Chi2 = 17.17, df = 8 (P = 0.03); I2 =53%
Test for overall effect: Z = 7.49 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours rosiglitaz. Favours control
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A P P E N D I C E S
Appendix 1. Search strategy
Search terms
Unless otherwise stated, search terms are free text terms; MesH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw =
text word; pt = publication type; sh = MeSH; adj = adjacent.
1. exp THIAZOLIDINEDIONES/
2. (rosiglitazon$ or thiazolidinedion$).tw.
3. 1 or 2
4. randomized controlled trial.pt.
5. controlled clinical trial.pt.
6. randomized controlled trials.sh.
7. random allocation.sh.
8. double-blind method.sh.
9. single-blind method.sh.
10. ((singl$ or doubl$ or tripl$ or trebl$) adj6 (mask$ or blind$)).tw.
11. (random$ adj25 (trial$ or stud$ or investigat$ or cross over or crossover)).tw.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp meta-analysis/
14. exp Review Literature/
15. meta-analysis.pt.
16. systematic review$.tw.
17. search$.tw.
18. medline.tw.
19. cochrane database of systematic reviews.jn.
20. 13 or 14 or 15 or 16 or 17 or 18 or 19
21. letter.pt.
22. comment.pt.
23. editorial.pt.
24. historical-article.pt.
25. 21 or 22 or 23 or 24
26. 20 not 25
27. exp Technology Assessment, Biomedical/
28. HTA.tw.
29. (health technology adj6 assessment$).tw.
30. (biomedical adj6 technology assessment$).tw.
31. 27 or 28 or 29 or 30
55Rosiglitazone for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
32. exp diabetes mellitus/
33. diabet$.tw.
34. IDDM.tw.
35. NIDDM.tw.
36. MODY.tw.
37. (late onset adj diabet$).tw.
38. (maturity onset adj diabet$).tw.
39. (non insulin$ depend$ or noninsulin$ depend$ or non insulin?depend$ or noninsulin?depend$).tw.
40. ((typ$ 1 or typ$ 2) adj6 diabet$).tw.
41. ((typ$ I or typ$ II) adj6 diabet$).tw.
42. (insulin$ depend$ or insulin?depend$).tw.
43. (T1DM or T2DM).tw.
44. 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. 3 and 12 and 44
46. 3 and 26 and 44
47. 3 and 31 and 44
48. 45 or 46 or 47
Appendix 2. Baseline characteristics (I)
Characteristic Derosa 2004 Derosa 2006a Derosa 2006b
I1: rosiglitazone 4 mg +
glimepiride 4 mg
C1: pioglitazone 15 mg +
glimepiride 4 mg
I1: rosiglitazone 4 mg + met-
formin 3000 mg
C1: pioglitazone 15 mg + met-
formin 3000mg
I1: rosiglitazone 4 mg + met-
formin 1500 mg
C1: glimepiride 2 mg+ met-
formin 1500 mg
Sex [%] I1: female 48; male 52
C1: female 53; male 447
I1: female 48; male 52
C1: female 50; male 50
I1: female 48; male 52
C1: female 51; male 49
Age [years], mean (SD) I1: 54 (5)
C1: 53 (6)
I1: 56 (4)
C1: 55 (5)
I1: 54 (4)
C1: 52 (5)
Ethnic groups [%] I1: white 100
C1: white 100
I1: caucasians 100
C1: caucasians 100
?
Duration of disease [years],
mean (SD)
I1: 6 (3)
C1: 5 (2)
I1: 5(4)
C1: 6(4)
I1: 5 (3)
C1: 4 (3)
Body mass index [kg/m2],
mean (SD)
I1: 24.3 (0.7)
C1: 24.4 (0.8)
I1: 26.4 (1.4)
C1: 26.9 (1.2)
I1: 26.6 (1.3)
C1: 26.8 (1.5)
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Pharmaco-naive patients [%] I1: none
C1: none
I1: none
C1: none
I1: none
C1: none
HbA1c [%], mean (SD) I1: 8.0 (0.8)
C1: 8.2 (0.7)
I1: 8.1 (0.9)
C1: 8.2 (0.8)
I1: 8.0 (0.7)
C1: 7.9 (0.6)
Co-morbidities [%] ? ? I1: hypertension 42
C1: hypertension 47
Notes patients who completed the
study
./. ./.
Footnotes
? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention-to -treat
Appendix 3. Baseline characteristics (II)
Characteristic Garber 2006 Goldberg 2005 Hanefeld 2007 Hällsten 2002 Jung 2005
I1: rosiglitazone 4
mg + metformin
2000
C1: glibenclamide
5 mg +metformin
1000 mg
I1: rosiglitazone 8
mg + diet
C1: pioglitazone 45
mg + diet
I1: rosiglitazone 4
mg + placebo
I2: rosiglitazone 8
mg + placebo
C1: glibenclamide +
placebo
I1: rosiglitazone 8
mg
C1: metformin 2 g
C2: placebo
I1: rosiglitazone 4
mg + glimepiride 4
mg
C1:
metformin 1000mg
+ glimepiride 4 mg
Sex [%] I1: female35; male
65
C1: female 44; male
56
I1: female 45; male
55
C1: female 46; male
54
I1: female 32; male
68
I2: female 42; male
58
C1: female 30; male
70
I1: female 29; male
71
C1: female 38; male
62
C2: female 29; male
71
I1: female 57; male
43
C1: female 54; male
46
Age [years], mean
(SD)
I1: 56
C1: 56
I1: 56.3 (11.3)
C1: 55.9 (10.5)
I1: 60.4 (8.2)
I2: 60.6 (9.2)
C1: 60.1 (8.3)
I1: 58.6 (7.5)
C1: 57.8 (7.9)
C2: 57.7 (7.1)
I1: 60 (8)
C1: 54 (14)
Ethnic groups [%] I1: white 79; black
6; hispanic/latino
10; asian/pacific is-
lander 3; other 3
C1: white 80; black
5; hispanic/latino
I1: white 60; his-
panic 32; asian 3;
african 3; other 2
C1: white 65; his-
panic 29; asian 3;
african 2; other 2
I1: white 99; other
1
I2: white 97; other
3
C1: white 99.5;
other 0.5
? I1: korean 100
C1: korean 100
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11; asian/pacific is-
lander 3; other 2
Duration of disease
[years], mean (SD)
I1: 6 (5)
C1: 5 (4)
I1: 4.0 (4.6)
C1: 3.9 (4.4)
I1: 5.9 (6.0)
I2: 6.0 (7.0)
C1: 6.4 (6.9)
newly diagnosed I1: 9 (5)
C1 : 7 (6)
Body
mass index [kg/m2],
mean (SD)
I1: 32 (5)
C1: 32 (5)
I1: 32.6 (6.6)
C1: 33.7 (12.9)
I1: 28.7 (3.7)
I2: 28.8 (3.7)
C1: 28.7 (3.9)
I1: 29.3 (3.7)
C1: 29.9 (4.0)
C2: 30.3 (4.5)
I1: 23.3 (2.6)
C1: 24.6 (2.4)
Pharmaco-naive pa-
tients [%]
I1: none
C1: none
Total: 8 I1: 42
I2: 38
C1: 38
? I1: none
C1: none
HbA1c [%], mean
(SD)
I1: 8.4 (1.1)
C1: 8.5 (1.2)
I1: 7.5 (1.2)
C1: 7.6 (1.2)
I1: 8.1 (1.3)
I2: 8.2 (1.4)
C1: 8.2 (1.3)
I1: 6.8 (0.8)
C1: 6.9 (0.7)
C2: 6.3 (0.4)
I1: 9.3 (0.9)
C1: 9.0 (0.8)
Co-morbidities [%] ? ? ? ? ?
Notes ./. ./. ./. SDs calculated text table data mis-
match
Footnotes
? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention-to-treat
Appendix 4. Baseline characteristics (III)
Characteristic Kahn 2006 Ko 2006 Lebovitz 2001 Ovalle 2004 Philipps 2001 Raskin 2004
Kahn 2006
I1: rosiglitazone
max. 8 mg
C1: metformin
max. 2 g
C2: glyburide
max. 15 mg
I1: rosiglitazone
max. 8 mg
+ (sulfonylurea
+/- metformin)
C1: “bedtime in-
sulin”
+ (sulfonylurea
+/- metformin)
I1: rosiglitazone
4 mg
I2: rosiglitazone
8 mg
C1: placebo
I1: rosiglitazone
8 mg
C1: insulin 70/
30
I1: rosiglitazone
4 mg
I2: rosiglitazone
2 x 2 mg
I3: rosigllitazone
8 mg
I4: rosiglitazone
2 x 4 mg
C1: placebo
I1: rosiglitazone
8 mg
C1: repaglinide
12 mg
C2: rosiglitazone
4 mg + repaglin-
ide 6 mg
Sex [%] I1: female 44;
male 56
C1: female 40;
I1: female 43;
male 57
C1: female 57;
I1: female 36;
male 64
I2: female 33;
? I1: female 41;
male 59
I2: female 41;
I1: female 47;
male 53
C1: female 38;
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male 60
C2: female 42;
male 58
male 43 male 67
C1: female 34;
male 66
male 59
I3: female 34;
male 66
I4: female 35;
male 65
C1: female 31;
male 69
male 62
C2: female 49;
male 51
Age [years],
mean (SD)
I1: 56.3 (10.0)
C1: 57.9 (9.9)
C2: 56.4 (10.2)
I1: 56.6 (10.7)
C1: 59.8 (11.2)
I1: 60 (9.8)
I2: 61 (9.5)
C1: 59 (10.9)
I1: 47 (12)
C1: 56 (14.1)
I1: 57.5 (9.9)
I2: 56.8 (9.4)
I3: 58.9 (9.9)
I4: 56.5 (9.7)
C1: 57.7 (9.2)
I1: 56.6 (10.8)
C1: 58.5 (10.1)
C2: 57.5 (10.8)
Ethnic groups
[%]
I1: white 87;
black 4; asian 3;
hispanic 5; other
1
C1: white 89;
black 4; asian 2;
hispanic 4; other
1
C2: white 89;
black 4; asian 2;
hispanic 4; other
0.3
Chinese patients I1: white 75;
black 8; other 16
I2: white 73;
black 9; other 17
C1: white 74;
black 8; other 18
? I1:
white 76; black
13; other 11
I2: white 78;
black 8; other 14
I3: white 80;
black 7; other 13
I4:
white 71; black
11; other 18
C1: white 79;
black 9; other 12
I1: caucasian 68;
black 13; his-
panic 0; other 19
C1: caucasian
63; black 16; his-
panic 2; other 19
C2: caucasian
65; black 17; his-
panic 3; other 15
Duration of dis-
ease [years],
mean (SD)
? I1: 11.8 (7.7)
C1: 13.6 (7.5)
I1: 4.8 (5.8)
I2: 5.4 (6.0)
C1: 4.6 (4.8)
I1: 7.6 (6.3)
C1: 7.6 (4.8)
I1: 5.4 (6.1)
I2: 5.5 (4.9)
I3: 6.1 (6.7)
I4: 5.9 (6.1)
C1: 6.6 (6.9)
I1: 7.4 (6.6)
C1: 7.2 (5.3)
C2: 7.3 (6.9)
Body mass index
[kg/m2], mean
(SD)
I1: 32.2 (6.7)
C1: 32.1 (6.1)
C2: 32.2 (6.3)
I1: 25.3 (3.8)
C1: 24.0 (2.7)
I1: 30.2 (4.1)
I2: 29.1 (3.9)
C1: 29.9 (4.1)
I1: 31.5 (6.9)
C1: 30.8 (7.6)
I1: 29.9 (4.1)
I2: 30.0 (4.2)
I3: 30.0 (4.3)
I4: 29.9 (4.3)
C1: 29.1 (4.2)
I1: 31.4 (5.2)
C1: 30.4 (4.7)
C2: 32.3 (5.2)
Pharmaco-naive
patients [%]
I1: 100
C1: 100
C2: 100
? I1: 26.5
I2: 26.6
C1: 28.5
I1: none
C1: none
I1: 22.1 (40/
181)
I2: 24.7 (46/
186)
I3: 29.3 (53/
181)
I4: 25.1 (47/
187)
C1: 22.5 (39/
173)
I1: none
C1: none
C2: none
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HbA1c [%],
mean (SD)
I1: 7.4 (0.9)
C1: 7.4 (0.9)
C2: 7.4 (0.9)
I1: 10.1 (1.0)
C1: 9.6 (0.9)
I1: 9.0 (1.5)
I2: 8.8 (1.6)
C1: 9.0 (1.7)
I1: 8.7
C1: 9.0
I1: 8.9 (1.6)
I2: 8.9 (1.5)
I3:8.9 (1.5)
I4:9.0 (1.5)
C1: 8.9 (1.5)
I1: 9.0
C1: 9.3
C2: 9.1
Co-morbidities
[%]
? ? ? ? ? ?
Notes antihypertensive
therapy:
I1: 51%; C1:
51%; C2: 52%
antihypertensive
agents:
I1: 55%; C1:
25%
lipid-lowering
agents:
I1: 9%; C1: 4%
ITT population SDs calculated ITT population ./.
Footnotes
? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention-to-treat
Appendix 5. Baseline characteristics (IV)
Characteristic Rosenstock 2006b Stocker 2007 Sutton 2002 Yang 2002
I1: rosiglitazone until 8
mg + sulfonyurea + max.
2 g metformin
C1:
insulin glargine max. 10
U + sulfonylurea + max.
2 g metformin
I1: rosiglitazone 4 mg
C1: metformin 1.7 g
I1: rosiglitazone 8 mg
C1: glyburide less than
20 mg
I1: rosiglitazone 4 mg
C1: placebo
Sex [%] I1:female 42; male 58
C1: female 55; male 45
I1: female 29; male 71
C1: female 47; male 53
I1: female 25; male 75
C1: female 29; male 71
I1: female 57; male 43
C1: female 62; male 38
Age [years], mean (SD) I1: 55.3 (11.4)
C1: 55.9 (10.5)
I1: 64 (11)
C1: 65 (10)
I1: 55.1 (9.0)
C1: 56.1 (8.9)
I1: 58.9 (9.4)
C1: 57.8 (8.9)
Ethnic groups [%] ? ? I1: white 73; black 5;
other 22
C1: white 76; black 3;
other 21
?
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Duration of disease
[years], mean (SD)
I1: 8.1 (5.1)
C1: 8.5 (5.8)
? I1: 5.3 (6.2)
C1: 6.2 (6.3)
?
Body mass index [kg/
m2], mean (SD)
I1: 33.6 (6.3)
C1: 34.6 (7.0)
I1: 29.4 (0.7)
C1: 29.7 (0.7)
>= 27:
I1: 67.3%
C1: 65.7%
I1: 25.8 (2.9)
C1: 25.8 (3.5)
Pharmaco-naive patients
[%]
I1: none
C1: none
I1: 24
C1: 28
I1: 21.2
C1: 18.2
I1: none
C1: none
HbA1c [%], mean (SD) I1: 8.7 (1.0) (ITT)
C1: 8.8 (1.0) (ITT)
I1: 8.5 (0.3)
C1: 8.5 (0.2)
I1: 9.1 (1.7)
C1: 9.5 (1.6)
I1: 9.5 (1.1)
C1: 9.7 (1.4)
Co-morbidities [%] cardiovascular disease
I1: 4.4
C1: 6.4
hypertension:
I1: 7.7
C1: 7.0
?
Notes ITT population:
for baseline characteris-
tics (112:105)
for HbA1c (112:104)
data
on statin, aspirin, beta-
blocker, calcium-chan-
nel blocker, angiotensin
receptor blocker , ACE
inhibitor and sulfony-
lurea use
./. ./.
Footnotes
? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention-to-treat
Appendix 6. Adverse events (I)
Characteristic Derosa 2004 Derosa 2006a Derosa 2006b
I1: rosiglitazone 4 mg +
glimepiride 4 mg
C1: pioglitazone 15 mg +
glimepiride 4 mg
I1: rosiglitazone 4 mg + met-
formin 3000 mg
C1: pioglitazone 15 mg + met-
formin 3000mg
I1: rosiglitazone 4 mg + met-
formin 1500 mg
C1: glimepiride 2 mg + met-
formin 1500 mg
[n] of participants who died I1: 0
C1: 0
? I1: 0
C1:0
[%] adverse events I1: 11.9 (5/42)
C1: 6.7 ( 3/45)
I1: 10.4 (5/48)
C1: 8.3 (4/48)
I: 12.5 (6/48)
C1:8.5 (4/47)
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[%] serious adverse events I1: 0
C1: 0
? ?
[%] drop-outs due to adverse
events
I1: 0
C1: 0
? ?
[%] oedema ? ? ?
haemoglobin [g/dl] ? ? ?
body weight [kg] ? ? I1: ?
C1: ?
body mass index (BMI) [kg/
m2]
I1: +1.5
C1: +1.2
I1: - 0.4
C1: -0.3
I1: -2.1
C1: -1.6
[%] hypoglycaemic episodes ? ? ?
[%] severe hypoglycaemic
episodes
? ? ?
Notes BMI change date calculated BMI change data calculated BMI change date calculated
Footnotes
? = unclear; I = intervention; C = control
Appendix 7. Adverse events (II)
Characteristic Garber 2006 Goldberg 2005 Hällsten 2002 Hanefeld 2007 Jung 2005
I1: rosiglitazone 4
mg + metformin
2000
C1: glibenclamide
5 mg +metformin
1000 mg
I1: rosiglitazone 8
mg + diet
C1: pioglitazone 45
mg+diet
I1: rosiglitazone 8
mg
C1: metformin 2 g
C2: placebo
I1: rosiglitazone (2
mg bid) + placebo
I2: rosiglitazone (4
mg bid) + placebo
C1: glibenclamide
up to 15 mg +
placebo
I1:
rosiglitazone 4 mg+
glimepiride 4mg
C1:
metformin 1000mg
+ glimepiride 4mg
[n] of participants
who died
? I1: 2
C1: 1
I1:0
C2:0
C1:0
I1: 0
I2: 0
C1: 0
?
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[%] adverse events I1: 63 (98/155)
C1: 68 (108/160)
? ? I1: 75.0 (150/200)
I2: 75.4 (144/191)
C1: 69.6 (144/207)
?
[%] serious adverse
events
I1: 6 (9/155)
C1: 4 (7/159)
? ? ? ?
[%] drop-outs due
to adverse events
I1: 4.4 (7/158)
C1: 10 (16/160)
I1: 2.7 (10/366)
C1: 2.7 (10/369)
I1:0
C2:0
C1:0
I1: 6
I2: 4.7
C1: 6.3
I1:?
C1: 3.3 (1/30)
[%] oedema ? ? ? I1: 3.5 (7/200)
I2: 8.9 (17/191)
C1: 1.9 (4/207)
?
haemoglobin [g/dl] ? ? ? I1: -0.48
I2: -0.98
C1: 0
?
body weight [kg] I1: +1.4
C1: +3
I1: 1.6
C1: 2.0
I1: + 0.6
C1: - 2.0
C2: + 0.1
I1: 1.75
I2: 2.95
C1: 1.9
?
body mass index
(BMI) [kg/m2]
? ? ? ? ?
[%] hypoglycaemic
episodes
I1: 26 (41/155)
C1: 73 (116/159)
? ? I1: 0.5 (1/200)
I2: 1.6 (3/191)
C1: 12.1 (25/207)
?
[%] severe hypogly-
caemic episodes
? ? ? I1:
I2:
C1: 0.01
?
Notes elevated levels of
ALT ( > 3x pretreat-
ment levels and >
upper normal limit)
:
I1: 2 patients
C1: 3 patients
I1 + C1: no signifi-
cant differences ob-
served for:
- liver functions
tests
- haemoglobin ans
haematocrit
- hypoglycemic
episodes
- adverse events
(oedema, congestive
heart failure)
body weight change
data calculated
two hypoglycaemic
events were severe
and one required
hospitalization; un-
clear in which med-
ication group these
events happened
./.
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Footnotes
? = unclear; I = intervention; C = control; AE = adverse event; ALT = alanine aminotransferase
Appendix 8. Adverse events (III)
Characteristic Kahn 2006 Ko 2006 Lebovitz 2001 Ovalle 2004 Philipps 2001 Raskin 2004
I1: rosiglitazone
max. 8 mg
C1: metformin
max. 2 g
C2: glyburide
max. 15 mg
I1: rosiglitazone
max. 8 mg
+ (sulfonylurea
+/- metformin)
C1: “bedtime in-
sulin”
+ (sulfonylurea
+/- metformin)
I1: rosiglitazone
4 mg
I2: rosiglitazone
8 mg
C1: placebo
I1: rosiglitazone
8 mg
C1: insulin 70/
30
I1: rosiglitazone
4 mg
I2: rosiglitazone
2 x 2 mg
I3: rosigllitazone
8 mg
I4: rosiglitazone
2 x 4 mg
C1: placebo
I1: rosiglitazone
8 mg
C1: repaglinide
12 mg
C2: rosiglitazone
4 mg + repaglin-
ide 6 mg
[n] of partici-
pants who died
I1: 34
C1: 31
C2: 31
? ? ? ? ?
[%] adverse
events
I1: 91.9 (1338/
1456)
C1: 92.2 (1341/
1454)
C2: 91.7 (1321/
1441)
I1: 7.1
C1: 10.7
I1: 73.1 (121/
166)
I2: 74.3 (126/
169)
C1: 69.9 (110/
158)
? I1+ I2+ I3+I4:
75
(551/ 735)
C1: 71 (123/
173)
I1: 24 (15/62)
C1:37 (23/63)
C2: 64 (81/127)
[%] serious ad-
verse events
I1: 23.8 (346/
1456)
C1: 22.8 (331/
1454)
C2: 21.4 (308/
1441)
I1: 5.4
C1: 0
? ? ? ?
[%]
drop-outs due to
adverse events
I1: 11.6
C1: 12.2
C2: 14.9
I1: 7.1
C1: 0
? ? I1+I2 +I3 +I4: 5.
6 (41/735)
C1: 10.8 (19/
173)
I1: 9.7 (6/62)
C1: 6.3 (4/63)
C2: 3.1 (4/127)
[%] oedema I1: 14.1 (205/
1456)
C1: 7.2 (104/
1454)
I1: 3.6
C1: 0
I1: 6 (10/166)
I2: 10.7(18/
169)
C1:1.9 (3/158)
? I1: 5.2 (10/181)
I2: 4.1 (8/ 186)
I3: 6.4 (12/181)
I4: 6.6 (13/187)
I1: 3 (2/62)
C1: 0
C2: 4 (5/125)
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C2: 8.5 (123/
1441)
C1: 1.6 (3/173)
haemoglobin [g/
dl]
? ? I1: -0.6
I2: -1.0
C1: ?
? I1+ I2+ I3+ I4 :
-0.5 to - 0.9
(dosage depen-
dent)
C: ?
I1: - 0.7
C1: 0
C2: - 0.8
body weight [kg] ? ? I1: 1.6
I2: 3.5
C1: -1
? I1: 1.2
I2: 1.5
I3: 2.6
I4: 3.3
C1: - 0.9
I1: + 2.3
C1: +1.6
C2: + 4.4
body mass index
(BMI) [kg/m2]
(SD)
? I1: 0.9 (1.3 )
C1: 0.8 (0.9)
change data after
one year
? ? ? ?
[%] hypogly-
caemic episodes
I1: 9.8 (142/
1456)
C1: 11.6 (168/
1454)
C2: 38.7 (557/
1441)
I1: 0
C1: 8.9
? ? ? I1: 2 (1/62)
C1: 6 (4/63)
C2: 9 (11/127)
[%] severe hypo-
glycaemic
episodes
I1: 0.1 (2/1456)
C1: 0.1 (1/
1454)
C2: 0.6 (8/1441)
I1: 0
C1: 0
? ? ? I1: 0
C1: 0
C2: <1 (1
episode)
Notes ./. ./. ./. ./. ITT population C1: one patient
with elevated
liver transam-
inase (>3X nor-
mal limit)
[n] fractures (%) Men
I1: 32 (3.95)
C1: 29 (3.36)
C2: 28 (3.35)
Women
I1: 60 (9.30)
C1: 30 (5.08)
C2: 21 (3.47)
Lower limb
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I1: 36 (5.58)
C1: 18 (3.05)
C2: 8 (1.32)
Upper limb
I1: 22 (3.41)
C1: 10 (1.69)
C2: 9 (1.49)
Spinal
I1: 1 (0.16)
C1: 1 (0.17)
C2: 1 (0.17)
[%] hospi-
talization for any
cause
I1: 11.6 (169/
1456)
C1: 11.8 (172/
1454)
C2: 10.4 (150/
1441)
[%] cardiovascu-
lar disease, total
events
I1: 4.3 (62/
1456)
C1: 4.0 (58/
1454)
C2: 2.8 (41/
1441)
[%]
congestive heart
failure, investiga-
tor-reported, to-
tal events
I1: 1.5 (22/
1456)
C1: 1.3 (19/
1454)
C2: 0.6 (9/1441)
[%] periph-
eral vascular dis-
ease, total events
I1: 2.5 (36/
1456)
C1: 1.9 (27/
1456)
C2: 2.2 (31/
1441)
[%] gastroin-
testinal events,
total events
I1: 23.0 (335/
1456)
C1: 38.3 (557/
1456)
C2: 21.9 (316/
1441)
[%] weight gain,
total events
I1: 6.9 (100/
1456)
C1: 1.2 (18/
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1456)
C2: 7.2 (104/
1441)
[%] haematocrit
>= 5 percentage
points below the
reference range
I1: 2.8 (41/
1456)
C1: 1.5 (22/
1456)
C2: 1.0 (14/
1441)
Footnotes
? = unclear; I = intervention; C = control
Appendix 9. Adverse events (IV)
Characteristic Rosenstock 2006b Stocker 2007 Sutton 2002 Yang 2002
I1: rosiglitazone max. 8
mg + sulfonyurea + met-
formin until 2000 mg
C1:
insulin glargine max. 10
U + sulfonylurea + met-
formin max. 2000 mg
I1: rosiglitazone 4 mg
C1: metformin 1.7 g
I1: rosiglitazone 8 mg
C1: glyburide less than
20 mg
I1: rosiglitazone 4 mg
C1: placebo
[n] of participants who
died
? I1: 0
C1: 0
? I1: none
C1: none
[%] adverse events I1: 28.6 (32/112)
C1: 6.7 (7/105)
? ? ?
[%] serious adverse
events
I1: 9.8 (11/112)
C1: 4.8 (5/105)
? ? ?
[%] drop-outs due to ad-
verse events
I1: 8 (9/112)
C1: 2 (2/105)
I1: 8.9 (4/45)
C1: 14.9 (7/47)
I1: 8 (8/104)
C1: 4 (4/99)
?
[%] oedema I1: 12.5 (14/112)
C1: 0
I1: 24.4 (11/45)
C1: 0
I1: 6.7 (7/104)
C1: 1 (1/99)
?
haemoglobin [g/dl] ? ? ? ?
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body weight [kg] I1: + 3
C1: + 1.7
I1: 1.6
C1: -2.0
I1: + 5
C1: + 3.4
I1: + 3.0
C1: - 0.4
body mass index (BMI)
[kg/m2]
? ? ? I1: + 1.2
C1: -0.4
[%] hypoglycaemic
episodes
I1: 42 (47/112)
C1: 55 (57/104)
? I1: 1.9 (2/104)
C1: 7.1 (7/99)
?
[%] severe
hypoglycaemic episodes
I1: 5.4 (6/112)
C1: 2.9 (3/104)
? I1: 0
C1: 3 (3/99)
?
Notes severe hypoglycemia =
plasma glucose < 36 mg/
dl or prompt recovery
after oral carbohydrate,
intravenous glucose or
glucagon adminstration
nocturnal hypoglycemia
= < 50 mg/dl:
I1: 3 events
C1: 10 events
safety was assessed in
the intent-to-treat (ITT)
population
./. cardiac related adverse
events:
I1: 15.4%; C1: 12.1%
heart disorder:
I1: 9/104.; C1:5/99
cardiomegaly:
I1: 5/104.; C1:2/99
I1: 1/104 clinical heart
failure
I1:2/104 initiated di-
uretic therapy as a result
of a fluid related event
C1: severe
hypoglycaemia:
3 of 7 total hypogly-
caemic episodes
Footnotes
? = unclear; I = intervention; C = control; AE = adverse events
Appendix 10. Primary outcomes
Characteristic Mortality Morbidity Adverse events Notes
Derosa 2004
I1: rosiglitazone 4 mg +
glimepiride 4 mg
C1: pioglitazone 15 mg
+ glimepiride 4 mg
not investigated not investigated see table ’Adverse events’ ./.
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Derosa 2006a
I1: rosiglitazone 4 mg +
metformin 3 g
C1: pioglitazone 15 mg
+ metformin 3 g
not investigated not investigated see table ’Adverse events’ ./.
Derosa 2006b
I1: rosiglitazone 4 mg +
metformin 1.5 g
C1: glimepiride 2 mg +
metformin 1.5 g
not investigated not investigated see table ’Adverse events’ ./.
Garber 2006
I1: rosiglitazone 4 mg +
metformin 2 g
C1: glibenclamide 5 mg
+ metformin 1 g
not investigated not investigated see table ’Adverse events’ ./.
Goldberg 2005
I1: rosiglitazone 8 mg
C1: pioglitazone 45 mg
not investigated not investigated see table ’Adverse events’ ./.
Hällsten 2002
I1: rosiglitazone 8 mg
I2: metformin 2 g
C1: placebo
not investigated not investigated see table ’Adverse events’ ./.
Hanefeld 2007
I1: rosiglitazone (2 mg
bid) + placebo
I2: rosiglitazone (4 mg
bid) + placebo
C1: glibenclamide up to
15 mg + placebo
not investigated not investigated see table ’Adverse events’ ./.
Jung 2005
I1: rosiglitazone 4 mg +
glimepiride 4 mg
C1: metformin 1 g +
glimepiride 4 mg
not investigated not investigated see table ’Adverse events’ ./.
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Kahn 2006
I1: rosiglitazone max. 8
mg
C1: metformin max. 2 g
C2: glyburide max. 15
mg
death rates reported but
not part of the efficacy
outcomes, as defined in
the publication of the
study design (Diabetes
Care 2002):
deaths from any cause
[no]:
I1: 34
C1: 31
C2: 31
morbidity rates reported
but not part of the ef-
ficacy outcomes, as de-
fined in the publication
of the study design (Di-
abetes Care 2002):
cardiovascular disease
[no (%)]:
serious / total events
I1: 49 (3.4) / 62 (4.3)
C1: 46 (3.2) / 58 (4.0)
C2: 26 (1.8) / 41 (2.8)
Peripheral vascular dis-
ease [no (%)]:
serious / total events
I1: 7 (0.5) / 36 (2.5)
C1: 6 (0.4) / 27 (1.9)
C2: 4 (0.3) / 31 (2.2)
see table ’Adverse events’ ./.
Ko 2006
I1: rosiglitazone max. 8
mg
+ (sulfonylurea +/- met-
formin)
C1: “bedtime insulin”
+ (sulfonylurea +/- met-
formin)
not investigated not investigated see table ’Adverse events’ ./.
Lebovitz 2001
I1: rosiglitazone 4 mg
I2: rosiglitazone 8 mg
C1: placebo
not investigated not investigated see table ’Adverse events’ ./.
Ovalle 2004
I1: rosiglitazone 8 mg
I2: insulin (premixed 70/
30)
not investigated not investigated see table ’Adverse events’ ./.
Philipps 2001
I1: rosiglitazone
4 mg o.d.; 2 mg b.i.d.; 8
mg o.d.; 4 mg b.i.d.
C1: placebo
not investigated not investigated see table ’Adverse events’ ./.
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Raskin 2004
I1: rosiglitazone 8 mg
I2: repaglinide 12 mg
C1: repaglinide + rosigli-
tazone 6 / 4 mg
not investigated not investigated see table ’Adverse events’ ./.
Rosenstock 2006b
I1: rosiglitazone 8 mg +
metformin 2g + sulfony-
lurea
C1: insulin glargine 10
units/day + metformin
2g + sulfonylurea
not investigated not investigated see table ’Adverse events’ ./.
Stocker 2007
I1: rosiglitazone 4 mg
C1: metformin 1.7 g
not investigated not investigated see table ’Adverse events’ ./.
Sutton 2002
I1: rosiglitazone 8 mg
C1: glyburide (mean 10.
5 mg)
not investigated not investigated see table ’Adverse events’ ./.
Yang 2002
I1: rosiglitazone 4 mg
C1: placebo
not investigated not investigated see table ’Adverse events’ ./.
Footnotes
? = unclear; I = intervention; C = control; o.d. = once daily; b.i.d. = twice daily
Appendix 11. Secondary outcomes
Characteristic Quality of life Costs HbA1c [%] (SD) Notes
Derosa 2004
I1: rosiglitazone 4 mg +
glimepiride 4 mg
not investigated not investigated I1:
end of study data: 6.7 (0.
9)
change data:
./.
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C1: pioglitazone 15 mg
+ glimepiride 4 mg
C1:
end of study data: 6.8 (0.
8)
change data:
Derosa 2006a
I1: rosiglitazone 4 mg +
metformin 3 g
C1: pioglitazone 15 mg
+ metformin 3 g
not investigated not investigated I1:
end of study data: 6.8 (0.
5)
change data: -1.3
C1:
end of study data: 6.8 (0.
3)
change data: -1.4
change data calculated
Derosa 2006b
I1: rosiglitazone 4 mg +
metformin 1.5 g
C1: glimepiride 2 mg +
metformin 1.5 g
not investigated not investigated I1:
end of study data: 6.8 (0.
6)
change data:
C1:
end of study data: 7.0 (0.
7)
change data:
./.
Garber 2006
I1: rosiglitazone 4 mg +
metformin 2 g
C1: glibenclamide 5 mg
+ metformin 1 g
not investigated not investigated I1:
end of study data:
change data: -1.1
C1:
end of study data:
change data: -1.5
“change data” from ab-
stract
Goldberg 2005
I1: rosiglitazone 8 mg
C1: pioglitazone 45 mg
not investigated not investigated I1:
end of study data:
change data: -0.6 (1.89)
C1:
end of study data:
change data: -0.7 (1.91)
SDs calculated
Hanefeld 2007
I1: rosiglitazone (2 mg
bid) + placebo
I2: rosiglitazone (4 mg
bid) + placebo
C1: glibenclamide up to
15 mg + placebo
not investigated not investigated I1:
end of study data:
change data: -0.3
I2:
end of study data:
change data: -0.5
I1:
end of study data:
change data: -0.7
./.
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Hällsten 2002
I1: rosiglitazone 8 mg
I2: metformin 2 g
C1: placebo
not investigated not investigated I1:
end of study data: 6.5 (0.
75)
change data:
I2:
end of study data: 6.2 (0.
72)
change data:
C1:
end of study data: 6.1 (0.
37)
change data:
SDs calculated
Jung 2005 I1: rosiglita-
zone 4 mg + glimepiride
4 mg C1: metformin 1 g
+ glimepiride 4 mg
not investigated not investigated I1:
end of study data: 7.8 (1.
1)
change data:
C1:
end of study data: 8.0 (1.
1)
change data:
./.
Kahn 2006
I1: rosiglitazone max. 8
mg
C1: metformin max. 2 g
C2: glyburide max. 15
mg
not yet reported but
mentioned in the pub-
lication of the study
design (Diabetes Care
2002)
not yet reported but
mentioned in the pub-
lication of the study
design (Diabetes Care
2002)
I1:
end of study data: 7.1
change data:
C1:
end of study data: 7.3
change data:
C2:
end of study data: 7.4
change data:
estimated from graph
(four year data)
Ko 2006
I1: rosiglitazone max. 8
mg
+ (sulfonylurea +/- met-
formin)
C1: “bedtime insulin”
+ (sulfonylurea +/- met-
formin)
not investigated not investigated I1:
end of study data: 9.1 (2.
0)
change data: -1.1 (1.7)
C1:
end of study data: 8.3 (1.
3)
change data: -1.3 (1.6)
./.
Lebovitz 2001
I1: rosiglitazone 4 mg
I2: rosiglitazone 8 mg
C1: placebo
not investigated not investigated I1:
end of study data:
change data: -0.3
I2:
end of study data
change data: -0.6
./.
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C1:
end of study data:
change data: +0.9
Ovalle 2004
I1: rosiglitazone 8 mg
C1: insulin (premixed
70/30)
not investigated not investigated I1:
end of study data: 7.8 (0.
5)
change data:
C1:
end of study data: 7.8 (0.
3)
change data:
./.
Philipps 2001
I1: rosiglitazone
4 mg o.d.; 2 mg b.i.d.; 8
mg o.d.; 4 mg b.i.d.
C1: placebo
not investigated not investigated pa-
tients who had received
prior oral monotherapy:
I1:
end of study data:
change data: 4 mg o.d.
(+0.14); 2 mg b.i.d. (+0.
02); 8 mg o.d. (-0.26); 4
mg b.i.d. (-0.54)
C1:
end of study data:
change data: +0.98
SDs calculated
Raskin 2004
I1: rosiglitazone 8 mg
I2: repaglinide 12 mg
C1: repaglinide + rosigli-
tazone 6 mg / 4 mg
not investigated not investigated I1:
end of study data: 8.5
change data: -0.56 (1.0)
I2:
end of study data: 9.1
change data: -0.17 (1.1)
C2:
end of study data: 7.7
change data: -1.43 (1.1)
SDs calculated
Rosenstock 2006b
I1: rosiglitazone 8 mg +
metformin 2g + sulfony-
lurea
C1: insulin glargine 10
units/day + metformin
2g + sulfonylurea
not investigated I1: $ 1,603
C1: $ 1,368
I1:
end of study data:
change data: -1.51
C1:
end of study data:
change data: -1.66
./.
Stocker 2007
I1: rosiglitazone 4 mg
C1: metformin 1.7 g
not investigated not investigated I1:
end of study data:
change data: -1.08 (0.
14)
(SE or SD)?
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C1:
end of study data:
change data: -1.19 (0.
13)
Sutton 2002
I1: rosiglitazone 8 mg
C1: glyburide (mean 10.
5 mg)
not investigated not investigated I1:
end of study data: 8.1 (0.
3)
change data:
C1:
end of study data: 8.4 (0.
2)
change data:
./.
Yang 2002
I1: rosiglitazone 4 mg
C1: placebo
not investigated not investigated I1:
end of study data:
change data: -0.7 (1.04)
C1:
end of study data:
change data: 0.4 (1.3)
./.
Footnotes
? = unclear; I = intervention; C = control; o.d. = once daily; b.i.d. = twice daily
Appendix 12. Changes to the published protocol
Changed items
The following changes to the published protocol with regards to ’types of intervention’ were implemented:
The following comparisons were acceptable for evaluation:
- rosiglitazone versus placebo;
- rosiglitazone versus another oral antidiabetic medication (meglitinide analogues, metformin, pioglitazone, sulphonylureas);
- rosiglitazone in combination with an oral antidiabetic medication or insulin versus a combination of an oral antidiabetic medication
or insulin (agents and treatment schemes had to be identical).
Excluded interventions:
Combination therapies consisting of different compounds in the treatment arms (for example rosiglitazone plus metformin versus
uptitration of metformin or rosiglitazone plus gliclazide versus gliclazide). Another Cochrane review will investigate rosiglitazone-
metformin combination therapies including different treatment regimens of these compounds. Furthermore, dipeptidyl peptidase-4
(DPP-4) inhibitors for type 2 diabetes mellitus are excluded, since these are the topic of another Cochrane review (Richter 2007), as
well as glucagon-like peptide analogues for type 2 diabetes mellitus (Cochrane review, Snaith 2007)
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Appendix 13. Risk of bias (I)
Characteristic Derosa 2004 Derosa 2006a Derosa 2006b
Intervention 1 (I1) / interven-
tion 2 (I2) / control 1 (C1)
I1: rosiglitazone + glimepiride
C1: pioglitazone + glimepiride
I1: rosiglitazone + metformin
C1: pioglitazone + metformin
I1: rosiglitazone + metformin
C1: glimepiride + metformin
Randomised controlled clinical
trial (RCT)
Y Y Y
Non-inferiority / equivalence
trial
N N N
Controlled clinical trial N N N
Design: parallel study Y Y Y
Design: crossover study N N N
Design: factorial study N N N
Crossover study: wash-out
phase
NA NA NA
Crossover study: carryover ef-
fect tested
NA NA NA
Crossover study: period effect
tested
NA NA NA
Method of randomisation randomisation codes prepared
by statistician
? drawing of envelopes; randomi-
sation codes prepared by a
statistician
Unit of randomisation (individ-
uals, cluster - specify)
individuals ? individuals
Randomisation stratified for
centres
? ? ?
Randomisation ratio 1:1 1:1 1:1
Concealment of allocation envelopes; a copy of the ran-
domisation code was provided
only to the statistician
envelopes containing randomi-
sation code; a copy of the ran-
domisation code was provoided
only for the statistician
?; drawing of envelopes
Stated blinding (open; single,
double, triple blind)
double-blind double-blind double-blind
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Actual blinding: participant Y Y Y
Actual blinding: caregiver /
treatment administrator
? ? ?
Actual blinding: outcome asses-
sor
? ? ?
Actual blinding: others ? ? ?
Blinding checked: participant N N N
Blinding checked: caregiver /
treatment administrator
N N N
Primary endpoint defined
(power calculation)
N N Y
[n] of primary endpoint(s) 6 5 5
[n] of secondary endpoints ? ? 6
Total [n] of endpoints ? ? 11
Prior publication of study de-
sign
N ? N
Outcomes of prior/current
publication identical
NA N N
Power calculation N N ?; see notes for details
[n] participants per group cal-
culated
NA NA ?; stated but no details provided
Non-inferiority trial: interval
for equivalence specified
NA NA NA
Intention-to-treat analysis
(ITT)
Y Y Y
Per-protocol-analysis N N N
ITT defined Y Y Y
Missing data: last observation
carried forward (LOCF)
? ? N
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Missing data: Other methods Y
Bonferroni
Y
Bonferroni
N
LOCF defined NA NA N
Analysis stratified for centres N ? N
[n] of screened patients (I1 / I2/
C1/ total)
? ? ?
[n] of randomised participants
(I1/ I2 / C1 / total) - primary
endpoint
I1: 42 (baseline)
C1: 45 (baseline)
total: 91
I1: 48 (baseline)
C1: 48 (baseline)
total: 103
I1: 48 (baseline)
C1: 47 (baseline)
total: 99
[n] of participants finishing the
study (I1/ I2 / C1 / total)
I1: 42
C1: 45
total: 87
I1: 48
C1:48
total: 96
I1: 48 (baseline)
C1: 47 (baseline)
total: 95
[n] of participants analysed (I1/
I2 / C1 / total) - primary end-
point
I1: 42
C1: 45
total: 87
I1: 48
C1:48
total: 96
?
Description of discontinuing
participants
N N N
Drop-outs (reasons explained) Y N N
Withdrawals (reasons
explained)
Y N Y
Losses-to-follow-up (reasons
explained)
N N N
[n] of participants who discon-
tinued (I1/ I2 / C1 / total)
I1: 2
C1: 2
total: 4
I1: ?
C1: ?
total: 7
I1: 2
C1: 2
total: 4
[%] discontinuation rate (I1/ I2
/ C1 / total)
I1: 5
C1: 4
total: 4
I1: ?
C1: ?
total: 6
I1: ?
C1: ?
total: 4
Discontinuation rate similar
between groups
Y ? Y
[%] crossover between groups ? ? ?
Differences [n] calculated to
analysed patients
NA ? ?
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Adjustment for multiple out-
comes / repeatedmeasurements
Y see comments N
Baseline characteristics: Clini-
cally relevant differences
N N N
Treatment identical (apart from
intervention)
N
some patients received be-
haviour modification, sessions
for weight-loss
Y Y
Compliance measured Y
pill count
Y
pill count
Y
pill count
Other important covariates
measured (specify)
N N N
Co-morbidities measured N N N
Co-medications measured Y N Y
Specific doubts about study
quality
Y
see notes
Y
see notes
?
Funding: commercial ? N ?
Funding: non-commercial ? N ?
Publication status: peer review
journal
Y Y Y
Publication status: journal sup-
plement
N N N
Publication status: abstract N N N
Publication status: other N N N
Notes patients were re-
quested to follow a controlled-
energy diet (ADA); some pa-
tients received behaviour mod-
ifications for weight-loss; ex-
ercise recommendations were
given; co-medications not spec-
ified for intervention vs control
patients were re-
quested to follow a controlled-
energy diet (ADA); patients re-
ceived behaviour modifications
for weight-loss; exercise recom-
mendations were given; adjust-
ment stated as Bonferroni but
P-values provided show no in-
dication of application of the
method; drop-outs per group
pa-
tients were requested to follow
a controlled-energy diet (ADA)
; all patients received behaviour
modifications for weight-loss;
exercise recommendations were
given; co-medication not spec-
ified for intervention vs con-
trol; publication in Pharma-
cotherapy 2005 states that a
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not specified power calculation was per-
formed whereas the publication
in Clinical Therapeutics 2005
states that no power calculation
was performed
Footnotes
Y = yes; N = no; ? = unclear I = intervention; C = control; (baseline) = if numbers for certain features could ne be derived from the
text, numbers from baseline characteristics were used
Appendix 14. Risk of bias (II)
Characteristic Garber 2006 Goldberg 2005 Hanefeld 2007 Hällsten 2002 Jung 2005
Intervention 1 (I1) /
intervention 2 (I2) /
control 1 (C1)
I1: rosiglitazone +
metformin
C1: glibenclamide +
metformin
I1: pioglitazone
C1: rosiglitazone
I1: rosiglitazone 4
mg + placebo
I2: rosiglitazone 8
mg + placebo
C1: glibenclamide +
placebo
I1: rosiglitazone
I2: metformin
C1: placebo
I1: rosiglitazone +
glimipiride
C1: metformin +
glimipiride
Randomised con-
trolled clinical trial
(RCT)
Y Y Y Y Y
Non-inferiority /
equivalence trial
N N Y N N
Controlled clinical
trial
N N N N N
Design: parallel
study
Y Y Y Y Y
Design: crossover
study
N N N N N
Design: factorial
study
N N N N N
Crossover study:
wash-out phase
NA NA NA NA NA
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Crossover
study: carryover ef-
fect tested
NA NA NA NA NA
Crossover study: pe-
riod effect tested
NA NA NA NA NA
Method of
randomisation
? stratified
for being previously
treated with oral an-
tidiabetic drugs and
according to sex
? ? ?
Unit of randomi-
sation (individuals,
cluster - specify)
individuals individuals individuals individuals individuals
Randomisation
stratified for centres
? N ? ? ?
Randomisation ra-
tio
1:1 1:1 1:1:1 1:1 1:1
Concealment of al-
location
? ? ? ? ?
Stated blinding
(open; single, dou-
ble, triple blind)
double-blind double-blind double-blind, dou-
ble-dummy
double-blind ?
Actual blinding:
participant
Y ? Y Y NA
Actual blind-
ing: caregiver / treat-
ment administrator
? ? ? ? NA
Actual blinding:
outcome assessor
? ? ? ? NA
Actual blinding:
others
? ? ? ? NA
Blinding checked:
participant
N N N N NA
Blinding
checked: caregiver /
treatment adminis-
N N N N NA
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trator
Primary endpoint
defined (power cal-
culation)
Y Y Y N N
[n] of primary end-
point(s)
1 1 1 ? ?
[n] of secondary
endpoints
7 16 13 ? ?
Total [n] of end-
points
8 17 14 13 10
Prior publication of
study design
N N N N N
Outcomes of prior/
current publication
identical
NA NA NA NA NA
Power calculation Y N Y N N
[n] participants per
group calculated
150 NA ? NA NA
Non-in-
feriority trial: inter-
val for equivalence
specified
NA NA Y NA NA
Intention-to-treat
analysis (ITT)
Y Y Y ? ?
Per-protocol-
analysis
N Y ? ? ?
ITT defined Y Y Y NA NA
Missing data: last
observation carried
forward (LOCF)
? Y Y N N
Missing data: Other
methods
N N N N N
LOCF defined NA N N NA NA
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Analysis stratified
for centres
N N ? N N
[n] of screened pa-
tients (I1 / I2/ C1/
total)
total: 356 total: 4410 total: 662 ? ?
[n] of randomised
participants (I1/ I2 /
C1 / total) - primary
endpoint
I1: 158
C1: 160
total: 318
I1: 369;
C1: 366;
total: 735
I1: 200
I2: 191
C1: 207
total: 598
I1: 15
I2: 16
C1: 14
total: 45
I1: 15
C1: 15
total: 30
[n] of participants
finishing the study
(I1/ I2 / C1 / total)
I1: 133
C1: 131
total: 264
I1: 299
C1: 286
total: 585
I1: 153
I2: 158
C1: 173
total: 484
I1: 14
I2: 13
C1: 14
total: 41
I1: 14
C1: 13
total: 27
[n] of participants
analysed (I1/ I2 /
C1 / total) - primary
endpoint
I1:
C1:
total: 305
I1: 363
C1: 356
total: 719
I1: 195
I2: 189
C1: 202
total: 586
(ITT population)
I1: 14
I2: 13
C1: 14
total: 41
I1: 14
C1: 13
total: 27
Description of dis-
continuing partici-
pants
N Y Y N N
Drop-outs (reasons
explained)
Y Y ? N Y
Withdrawals
(reasons explained)
Y Y Y Y N
Losses-to-follow-up
(reasons explained)
? Y ? N N
[n]
of participants who
discontinued (I1/ I2
/ C1 / total)
I1: 25
C1: 29
total: 54
I1: 70
C1: 80
total: 150
I1: 47
I2: 33
C1: 34
total: 114
I1: 1
I2: 3
C1: 0
total: 4
I1: 1
C1: 2
total: 3
[%] discontinuation
rate (I1/ I2 / C1 / to-
tal)
I1: 16
C1: 18
total: 17
I1: 19
C1: 22
total: 20
I1: 23.5
I2: 17.3
C1: 16.4
total: 19
I1: 7
I2: 19
C1: 0
total: 9
I1: 7
C1: 13
total: 10%
Discontinuation
rate similar between
groups
N Y N ? Y
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[%] crossover be-
tween groups
? ? ? ? ?
Differences [n] cal-
culated to analysed
patients
N NA ? NA NA
Adjust-
ment for multiple
outcomes / repeated
measurements
N N N N N
Baseline characteris-
tics: Clinically rele-
vant differences
Y
9% more men in I1
than C
N N
rosiglitazone 8 mg
less male partici-
pants)
?
HbA1c not
included in baseline
characteristics
?
HbA1c and resistin
not
included in baseline
characteristics
Treatment identical
(apart from inter-
vention)
Y Y Y Y Y
Compliance
measured
N N N Y N
Other important
covariates measured
(specify)
N N N N N
Co-morbidities
measured
N Y N N N
Co-medications
measured
N N N N N
Specific doubts
about study quality
N N N N N
Funding: commer-
cial
Y Y Y Y N
Funding: non-com-
mercial
? ? N Y Y
Publication status:
peer review journal
N Y Y Y N
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Publication status:
journal supplement
N N N N N
Publication status:
abstract
N N N N N
Publication status:
other
N N N N N
Notes commercial funding
not explicitly stated
but three of five au-
thors from pharma-
ceutical company
no quantitative data
on adverse events
sample size not re-
ported, LOCF pa-
rameter
unclear, baseline no
of participants 587
patients
receivedwritten diet
instructions
poor reporting on
quality criteria
Footnotes
Y = yes; N = no; ? = unclear I = intervention; C = control; (baseline) = if numbers for certain features could ne be derived from the
text, numbers from baseline characteristics were used
Appendix 15. Risk of bias (III)
Characteristic Kahn 2006 Ko 2006 Lebovitz 2001 Ovalle 2004 Phillips 2001 Raskin 2004
Intervention
1 (I1) / interven-
tion 2 (I2) / con-
trol 1 (C1)
I1: rosiglitazone
I2: metformin
C1: glyburide
I1: rosiglitazone
+ (sulfonylurea
+/- metformin)
C1: bedtime iso-
phane insulin +
(sulfonylurea +/-
metformin)
I1: rosiglitazone
2 mg
I2: rosiglitazone
4 mg
C1: placebo
I1: rosiglitazone
+ glimepiride +
metformin +
C1: glimepiride
+ metformin +
70/30 mixed hu-
man insulin
I1: rosiglitazone
4 mg
od I2: rosiglita-
zone 2mgbid I3:
rosiglitazone 8
mg od I4: rosigli-
tazone 4 mg bid
C1: placebo
I1: rosiglitazone
I2: repaglinide
C1: rosiglitazone
+ repaglinide
Randomised
controlled clini-
cal trial (RCT)
Y Y Y Y Y Y
Non-inferiority /
equivalence trial
N N N N Primary hypoth-
esis: superiority
of rosiglitazone
vs placebo; sec-
ondary hypoth-
esis: equivalence
of once daily vs
?
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twice daily ad-
ministration of
rosiglitazones
Controlled clini-
cal trial
N N N N N N
Design: parallel
study
Y Y Y Y Y Y
Design:
crossover study
N N N N N N
Design: factorial
study
N N N N N N
Crossover study:
wash-out phase
NA NA NA NA NA NA
Crossover study:
carryover effect
tested
NA NA NA NA NA NA
Crossover study:
period effect
tested
NA NA NA NA NA NA
Method of ran-
domisation
stratified accord-
ing to sex in
blocks of six
? ? ? ? ?
Unit of randomi-
sation (individu-
als, cluster - spec-
ify)
individuals individuals individuals individuals individuals individuals
Randomisa-
tion stratified for
centres
N NA ? NA ? ?
Randomisation
ratio
1:1:1 1:1 1:1 1:1 1:1:1:1:1 1:1:2
Concealment of
allocation
Y ? ? ? ? ?
Stated blind-
ing (open; single,
double, triple
blind)
double-bind open double-blind ? double-blind open
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Actual blinding:
participant
? NA Y ? ? N
Actual blinding:
care-
giver / treatment
administrator
? NA ? ? ? N
Actual blinding:
outcome assessor
? ? ? ? ? ?
Actual blinding:
others
Y ? N N N ?
Blinding
checked: partici-
pant
N NA N N N NA
Blinding
checked: care-
giver / treatment
administrator
N NA N N N NA
Primary
endpoint de-
fined (power cal-
culation)
Y Y N N N Y
[n] of primary
endpoint(s)
1 1 1 1 1 1
[n] of secondary
endpoints
? ? 10 6? 8 7
Total [n] of end-
points
? 9 11 7 9 8
Prior publication
of study design
Y N N N N N
Out-
comes of prior/
current publica-
tion identical
? NA NA NA NA NA
Power
calculation
Y Y N N N Y
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[n] participants
per group calcu-
lated
3600 (initially)
; 4182 (March
2002);
further extension
of trial was de-
cided in Febru-
ary 2004 to com-
pensate
withdrawals
50 NA NA NA total: 190
Non-in-
feriority trial: in-
terval for equiva-
lence specified
NA NA NA NA Y NA
Intention-
to-treat analysis
(ITT)
Y Y Y ? Y Y
Per-protocol-
analysis
NA N ? ? N ?
ITT defined N N Y NA Y Y
Miss-
ing data: last ob-
servation carried
forward (LOCF)
N ? Y ? Y N
Missing data:
Other methods
N ? N N N Y
LOCF defined NA ? Y NA N NA
Analysis strati-
fied for centres
N NA Y NA N N
[n] of screened
patients (I1 / I2/
C1/ total)
total: 6676 ? total: 623 total: ? total: 1503 total: ?
[n] of
randomised par-
ticipants (I1/ I2 /
C1 / total) - pri-
mary endpoint
I1: 1456
I2: 1454
C1: 1441
total: 4351
I1: 56
C1: 56
total: 112
I1: ?
I2: ?
C1: ?
total: 533
I1: 9
C1: 8
total: 17
I1: ?
I2: ?
I3: ?
I4: ?
C1: ?
total: 959
I1: 62
I2: 63
I3: 127
total: 252
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[n] of
participants fin-
ishing the study
(I1/ I2 / C1 / to-
tal)
I1: 917
I2: 903
C1: 807
total: 2627
I1: 50
C1: 52
total: 102
I1: ?
I2: ?
C1: ?
total: 365
I1: ?
C1: ?
total: ?
I1: ?
I2: ?
I3: ?
I4: ?
C1: ?
total: ?
I1: 37
I2: 38
I3: 106
total: 181
[n] of partici-
pants anal-
ysed (I1/ I2 / C1
/ total) - primary
endpoint
I1: 1393
I2: 1397
C1: 1337
total: 4127
I1: ?
C1: ?
total: ?
I1: ?
I2: ?
C1: ?
total: 472
I1: ?
C1: ?
total: ?
I1: 181
I2: 186
I3: 181
I4: 187
C1: 173
total: 908
I1: 55
I2: 59
I3: 126
total: 240
Description
of discontinuing
participants
N Y N N N N
Drop-outs (rea-
sons explained)
N Y
partly
N N N Y
With-
drawals (reasons
explained)
Y N N N Y N
Losses-to-fol-
low-up (reasons
explained)
N N N N N N
[n] of partici-
pants who dis-
continued (I1/
I2 / C1 / total)
I1: 539
I2: 551
C1: 634
total: 1724
I1: 6
C1: 2
total: 8
I1: 46
I2: 45
C1: 77
total: 168
I1: ?
C1: ?
total: ?
I1: ?
I2: ?
I3: ?
I4: ?
C1: ?
total: 51
I1: 25
I2: 25
I3: 21
total: 71
[%] discontinua-
tion rate (I1/ I2 /
C1 / total)
I1: 37
I2: 38
C1:44
total: 44
I1: 10.7
C1: 3.6
total: 7.1
I1: 26
I2: 25
C1: 44
total: 32
I1: ?
C1: ?
total: ?
I1: ?
I2: ?
I3: ?
I4: ?
C1: ?
total: 5%
I1: 40.3
I2: 39.7
I3: 16.5
total: 28.2
Discontinu-
ation rate similar
between groups
? N N ? N
“pa-
tients who with-
drew from treat-
ment were more
N
discontin-
uation rate lower
for repaglinide/
rosigli-
89Rosiglitazone for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
poorly con-
trolled at base-
line”
tazone combina-
tion therapy due
to
lack of efficiency
in themonother-
apy groups
[%] crossover be-
tween groups
? ? ? ? ? ?
Differences
[n] calculated to
analysed patients
additional
patients were re-
cruited during
the study
N NA NA NA N
Adjustment
for multiple out-
comes / repeated
measurements
N ? Y N Y N
Baseline char-
acteristics: Clini-
cally relevant dif-
ferences
Y Y
gender, HbA1c,
metformin
dosage, antihy-
per-
tensive and lipid-
lowering agents
N ?
only few charac-
teristics re-
ported, numeri-
cal differences in
age
N previous
sulfonylurea /
metformin treat-
ment
Treatment iden-
tical (apart from
intervention)
Y Y Y there was no
titration period
in the rosiglita-
zone group
Y Y
Compliance
measured
N N N N N N
Other important
covariates mea-
sured (specify)
N N N N N N
Co-morbidities
measured
N N N N N N
Co-medications
measured
N Y N N N N
Specific doubts
about study
quality
N N N Y N N
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(Continued)
Funding:
commercial
Y ? ? Y ? Y
Funding: non-
commercial
? ? ? ? ? ?
Publication sta-
tus: peer review
journal
Y Y Y Y Y Y
Publication sta-
tus: journal sup-
plement
N N N N N N
Publication sta-
tus: abstract
N N N N N N
Publication sta-
tus: other
N N N N N N
Notes 24 weeks treat-
ment duration as
inclusion crite-
rion
./. authors from
a pharmaceutical
company
./. two authors hold
stocks in phar-
maceutical com-
panies
./.
Footnotes
Y = yes; N = no; ? = unclear I = intervention; C = control; (baseline) = if numbers for certain features could ne be
derived from the text, numbers from baseline characteristics were used
Appendix 16. Risk of bias (IV)
Characteristic Rosenstock 2006b Stocker 2007 Sutton 2002 Yang 2002
Intervention 1 (I1) / in-
tervention 2 (I2) / con-
trol 1 (C1)
I1: rosiglitazone + sul-
fonylurea + metformin
C1: insulin
glargine + sulfonylurea +
metformin
I1: rosiglitazone
C1: metformin
I1: rosiglitazone
C1: glyburide
I1: rosiglitazone
C1: placebo
Randomised controlled
clinical trial (RCT)
Y Y Y Y
Non-inferiority / equiv-
alence trial
? N Y N
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(Continued)
Controlled clinical trial N N N N
Design: parallel Y Y Y Y
Design: crossover study N N N N
Design: factorial study N N N N
Crossover study: wash-
out phase
NA NA NA NA
Crossover study: carry-
over effect tested
NA NA NA NA
Crossover study: period
effect tested
NA NA NA NA
Method of randomisa-
tion
? random number genera-
tor, stratified by the use
of statins
? ?
Unit of randomisation
(individuals, cluster -
specify)
? individuals ? ?
Randomisation stratified
for centres
? NA ? ?
Randomisation ratio 1:1 1:1 1:1 1 : 1
Concealment of alloca-
tion
? “allocation-concealed
randomization”
? ?
Stated blind-
ing (open; single, dou-
ble, triple blind)
open open open double-blind
Actual blinding: partici-
pant
N NA N Y
Actual blinding: care-
giver / treatment admin-
istrator
N NA N ?
Actual blinding: out-
come assessor
? Y ? ?
Actual blinding: others N N N N
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(Continued)
Blinding checked: par-
ticipant
NA NA NA N
Blinding checked: care-
giver / treatment admin-
istrator
NA NA NA N
Primary endpoint de-
fined (power calculation)
Y Y Y N
[n] of primary endpoint
(s)
1 1 1 1
[n] of secondary end-
points
7 2 10 10
Total [n] of endpoints 8 8 11 11
Prior publication of
study design
N N N N
Outcomes of prior/cur-
rent publication identi-
cal
NA NA NA NA
Power calculation N Y Y N
[n] participants per
group calculated
NA 40 60 NA
Non-inferiority trial: in-
terval for equivalence
specified
NA NA Y NA
Intention-to-treat analy-
sis (ITT)
Y N Y ?
Per-protocol-analysis N Y Y ?
ITT defined Y NA Y N
Missing data: last ob-
servation carried forward
(LOCF)
Y N Y ?
Missing data: Other
methods
N N N N
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(Continued)
LOCF defined N NA N N
Analysis stratified for
centres
Y NA N ?
[n] of screened patients
(I1 / I2/ C1/ total)
total: 341 total: 120 total: 351 ?
[n] of randomised partic-
ipants (I1/ I2 / C1 / to-
tal) - primary endpoint
I1: ?
C1: ?
total: 219
I1: 45
C1: 47
total: 92
I1: 104
C1: 99
total: 203
?
[n] of participants finish-
ing the study (I1/ I2 / C1
/ total)
I1: ?
C1: ?
total: ?
I1: ?
C1: ?
total:
I1: ?
C1: ?
total: 130
?
[n] of participants anal-
ysed (I1/ I2 / C1 / total)
- primary endpoint
I1: 105
C1: 112
total: 216
I1: 37
C1: 38
total: 75
I1: ?
C1: ?
total: ?
I1: 30
C1: 34
total: 64
Description of discon-
tinuing participants
Y Y Y N
Drop-outs (reasons ex-
plained)
N Y N N
Withdrawals (reasons
explained)
Y Y Y N
Losses-to-follow-up
(reasons explained)
N NA N N
[n] of participants who
discontinued (I1/ I2 /C1
/ total)
I1: 11
C1: 7
total: 18
I1: 8
C1: 9
total: 17
I1: 40
C1: 34
total: 74
I1: ?
C1: ?
total: ?
[%] discontinuation rate
(I1/ I2 / C1 / total)
I1: ?
C1: ?
total: 8
I1: 17.8
C1: 19.2
total: 18.5
I1: 38
C1: 34
total: 36
I1: ?
C1: ?
total: ?
Discontinuation rate
similar between groups
Y Y Y ?
[%] crossover between
groups
? ? ? ?
Differences [n] calcu-
lated to analysed patients
NA N N NA
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(Continued)
Adjustment for multi-
ple outcomes / repeated
measurements
N N N ?
Baseline characteristics:
Clinically relevant differ-
ences
Y
sex
Y
medications, sex
N N
baseline val-
ues for adiponectin not
reported
Treatment
identical (apart from in-
tervention)
Y Y Y Y
Compliance measured N Y
patient surveys, prescrip-
tion renewals, pill counts
N N
Other important covari-
ates measured (specify)
N N N N
Co-morbidities
measured
N Y
partly
N N
Co-medications
measured
N Y N N
Specific doubts about
study quality
Y N Y Y
Funding: commercial Y Y ? Y
Funding: non-commer-
cial
N N N ?
Publication status: peer
review journal
Y Y Y Y
Publication status: jour-
nal supplement
N N N N
Publication status: ab-
stract
N N N N
Publication status: other N N N N
Notes allocation concealment
unclear, blinding of out-
come assessor unclear,
open design
open design, unclear
outcome assessment
one author employed by
GlaxoSmithKline
unclear how many pa-
tients were randomised,
how many discontin-
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(Continued)
ued, were withdrawn or
lost to follow-up; effi-
cacy evaluation seems to
be published in a differ-
ent publication; unclear
if patients were still ran-
domised under this fol-
low-up study
Footnotes
Y = yes; N = no; ? = unclear I = intervention; C = control; (baseline) = if numbers for certain features could ne be derived from the
text, numbers from baseline characteristics were used
F E E D B A C K
Dollow, July 2007
Summary
The following query was made on 18 July 2007:
The Cochrane Collaboration has a reputation for robustness of analysis and integrity of data interpretation. Therefore, it was disap-
pointing to read the conclusions made in the recent Cochrane Review written by Richter et al, titled, “Rosiglitazone for type 2 diabetes
mellitus.”
The authors drew conclusions regarding the impact of rosiglitazone on mortality and morbidity by reviewing a limited number of
short term studies (18) primarily designed to assess glycaemic control. This analysis cannot provide a full picture of all the research
conducted with rosiglitazone. The conclusions provide no new evidence about the role of rosiglitazone in clinical practice. In addition,
the conclusions regarding cardiovascular safety disagree with the authors’ own meta-analysis on myocardial infarction which could not
confirm an increased risk.
The studies assessed in the review contained no stratification for baseline cardiovascular risk, leading to unavoidable imbalances between
rosiglitazone and control groups. Most importantly the authors fail to include the interim findings of RECORD(1), a prospective long-
term study primarily designed to evaluate the profile of rosiglitazone with respect to cardiovascular disease. The RECORD(1) data was
available as an online publication some six weeks prior to the publication of this review. Its exclusion is surprising and adds question
to the robustness of the authors’ conclusions.
Questions about the safety of rosiglitazone should be answered by reviewing all relevant evidence, in particular long-term prospective
trials. The conclusion regarding the cardiovascular data from ADOPT(2,3) are puzzling, given that in ADOPT(2,3) all major adverse
cardiovascular events (MACE) were analysed and found to be rare in this population and comparable for all treatments - rosiglitazone,
glibenclamide and metformin.. Additionally, no excess in mortality with rosiglitazone was seen overall. The significant benefits of
rosiglitazone in maintaining the duration of glycaemic response in ADOPT(2) are unfortunately not given similar prominence.
The interim findings of RECORD(1), the only study specifically designed to look at cardiovascular outcomes with rosiglitazone,
does not show evidence of a difference in cardiovascular death between rosiglitazone and control groups. Additionally, no significant
differences for myocardial infarction between groups were seen.
The totality of the data - including long-term studies such as ADOPT(2) and RECORD(3) and a real-world epidemiological analysis
of 33,000 patients(5) - show that rosiglitazone has a comparable ischaemic cardiovascular profile to the most commonly used oral anti-
diabetic medicines, metformin and sulphonylureas.
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With respect to the analysis of glycaemic efficacy, it is puzzling that the authors excluded a number of studies which are applicable
to decisions made in clinical practice, such as Bailey et al(4) in which uptitration of metformin is compared with metformin and
rosiglitazone. Additionally, whilst a significant decrease in the rate of hypoglycaemia associated with rosiglitazone is reported in the
results section of the review, this is not referred to in the authors’ conclusions. Instead, only oedema is mentioned, which is a well
recognised side-effect of thiazolidenedione therapy.
The studies selected for use in a Cochrane systematic review should be appropriate to the purpose of the review. It is therefore difficult
to understand how the limited range of studies selected from the much larger number of studies available, allow the authors to draw
robust conclusions with respect to morbidity, mortality and health-outcomes for rosiglitazone. In addition, the conclusions drawn
regarding ischaemic cardiovascular safety should be substantiated by the data analysed and not inferred from statistically insignificant
odds ratios.
Finally we question the appropriateness of raising comment about the timing of data release to regulatory authorities and regulatory
approval requirements in diabetes as part of a systematic review. GSK has actively shared data on rosiglitazone with regulatory agencies
worldwide in a timely manner. The company carries out its clinical trials with the highest level of ethical conduct and is committed to
patient safety.
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ADOPT - A Diabetes Outcome Progression Trial
RECORD - Rosiglitazone Evaluated for Cardiovascular Outcomes
Reply
The comments by Dr Dollow are answered in a point-by-point fashion:
The Cochrane Collaboration as well as the Metabolic and Endocrine Disorders Group adhere to high quality standards. It is unclear
how Dr Dollow defines “integrity of data interpretation”. As a matter of course, the discussion and conclusion sections are firmly based
upon the data evaluated in our review.
The types of interventions we included had to have a minimum trial duration of 24 weeks. The point that a limited number of
studies had a longer duration, for example more than one year, is due to the fact that neither the manufacturer nor the scientific
community seems to be interested in the long-term benefit-risk ratio of rosiglitazone therapy, but cannot be attributed to the review
itself. Furthermore, the bulk of studies investigated glycaemic control as primary efficacy endpoint and not patient-oriented parameters
like mortality, morbidity and health-related quality of life which again has to be ascribed to the deficiencies of studies but not the
systematic review. Our review so far provides the best overview of the risks and (with regard to relevant outcomes) missing benefits of
rosiglitazone therapy and therefore is of great importance for clinical practice.We did not perform our ownmeta-analysis on myocardial
infarction but tried to replicate the findings by Nissen et al using their data in the discussion section of our review (Nissen 2007).
Cardiovascular disease and safety in their clinical meaning include more than myocardial infarction, for example increased risk of
congestive heart failure following rosiglitazone therapy. Therefore, we stand by the conclusions as stated in the review.
The studies and publications we discovered and assessed in our review - with the exception of the ADOPT (A Diabetes Outcome
Progression Trial) - did not investigate cardiovascular risk. That is one of the reasons why Nissen et al (Nissen 2007) had to search
the manufacturer’s as well as drug authorities web sites. The publication schedule of the Cochrane Library demands from Cochrane
review groups to hand in their “module” (all new and updated protocols and reviews) around two months before the publication of the
Cochrane Library. Therefore, the interim findings of the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation
of Glycaemia in Diabetes) study could not be included in our review (Home 2007). Furthermore, these interim data do not provide
assurance of the cardiovascular safety of rosiglitazone treatment in type 2 diabetes mellitus (see below).
We agree that questions about the safety of rosiglitazone should be answered by critical appraisal of especially well-performed long-
term randomised controlled clinical trials. With regard to the cardiovascular data from the ADOPT trial Dr Dollow mentions a letter
to the Lancet editor by Dr Krall, Chief Medical Officer of GlaxoSmithKline. It is of interest to note that this letter to the editor which
refers to the Nissen et al publication was published in the Lancet and not the New England Journal of Medicine where the study
originally was published. The new endpoint MACE (major adverse cardiovascular events, that is all cardiovascular deaths, myocardial
infarction serious adverse events (fatal and non-fatal), and stroke serious adverse events (fatal and non-fatal)) was not part of the original
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publication of the ADOPT trial, resulted from a post-hoc analysis by the manufacturer and “forgot” to mention congestive heart
failure which was part of the outcomes contributing to the overall endpoint cardiovascular disease. Here, significant differences between
glyburide (glibenclamide) and rosiglitazone were reported, indicating increased cardiovascular disease risk after rosiglitazone therapy, as
mentioned in our review. The ADOPT trial was not powered to investigate mortality. The primary outcome time from randomisation
to treatment failure as measured by elevated fasting plasma glucose levels was not part of our pre-specified outcomes but we agree
with the accompanying New England Journal of Medicine editorial stating “the choice of time to failure based on a confirmed fasting
glucose level of more than 180 mg per deciliter as the primary outcome, rather than one based upon glycated hemoglobin levels, seems
anachronistic ” (Nathan 2006).
The unscheduled interim analysis from the RECORDtrial should not be interpreted as evidence for cardiovascular safety of rosiglitazone
therapy (Home 2007). We once again agree with the statements of the associated editorial in the New England Journal of Medicine
(Nathan 2007):
“The primary end point of the RECORD trial consists of an aggregate of time to first hospitalization for a cardiovascular event or
death from cardiovascular causes” ... “Unfortunately, this interim analysis, performed after a mean of 3.75 years (about 60% of the
planned 6-year duration of the study) fails to provide exculpatory evidence” ... “RECORD extremely underpowered for the primary
outcome” ... “the results of this underpowered interim analysis suggest a possible adverse effect of treatment with rosiglitazone on the
primary outcome, rather than the benefit that was hypothesized ... considering the low power of the study and the trend for more
adverse outcomes in the rosiglitazone-treated group, it is highly unlikely that the study will ever establish a cardiovascular benefit for
rosiglitazone” ... “In the aggregate, however, these analyses support a concern regarding the safety of rosiglitazone” ... “It is reasonable to
ask whether physicians should feel comfortable using a drug that might have an 8% excess risk of severe cardiovascular disease or death
from cardiovascular causes” ... “Unless further studies provide convincing assurance that treatment with rosiglitazone does not increase
the risk of cardiovascular disease, the largely circumstantial evidence of the meta-analyses and the nonsignificant trend in the current
report from the RECORD trial must be taken seriously” ... “The jury may still be out with regard to the cardiotoxicity of rosiglitazone,
but when it comes to patient safety, ”first, do no harm“ should outweigh any presumption of innocence.”
As demonstrated above, the totality of data do not show that rosiglitazone has a comparable ischaemic cardiovascular profile to the
most commonly used oral antidiabetic medicines. To claim a comparable ischaemic cardiovascular risk profile especially to metformin
in obese type 2 diabetes patients appears careless: Contrary to rosiglitazone treatment metformin positively influences patient-oriented
outcomes since the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that patients allocated metformin had
significant reductions for any-diabetes related endpoint, diabetes-related death, stroke and all-cause mortality (UKPDS-34).
Dr Dollow claims that “authors excluded a number of studies which are applicable to decisions made in clinical practice, such as Bailey
et al(4) in which uptitration of metformin is compared with metformin and rosiglitazone”. In the ’criteria for considering studies
for this review’ we clearly exemplified under ’excluded interventions’: “Combination therapies consisting of different compounds in
the treatment arms (for example rosiglitazone plus metformin versus uptitration of metformin or rosiglitazone plus gliclazide versus
gliclazide). Another Cochrane review will investigate rosiglitazone-metformin combination therapies including different treatment
regimens of these compounds.” We want to perform another Cochrane review on different combination partners because it does not
appear to be adequate to compare interventions with different combination partners neglecting the complicated interplay of various
agents. Furthermore, we did not report on a significant decrease in the rate of hypoglycaemia associated with rosiglitazone but stated
“Seven of the 18 included studies showed data on hypoglycaemic episodes: Compared to active monotherapy control rosiglitazone
treatment resulted in somewhat lower rates of hypoglycaemia, especially when compared to sulphonylureas. Severe hypoglycaemic
events were rarely reported.” Apart from that, serious adverse events were noted more often after rosiglitazone treatment as were higher
median discontinuation rates compared to control therapy.
Our studies selected for this review were indeed appropriate to our objectives. To speak of a “limited range of studies selected from
the much larger number of studies available” does not understand our strategy. We especially focused on patient-oriented parameters
like mortality, morbidity, health-related quality of life and adequately reported on all available study results according to our in- and
exclusion criteria. Unfortunately, the availability of sound studies is scarce due to the fact that concerning this matter only the ADOPT
and the RECORD trial provide some hypotheses about the benefit-risk ratio of rosiglitazone therapy which does not appear to be
positive (see above).
According to Krall (Krall 2007), GlaxoSmithKline performed similar meta-analyses in 2005 and 2006 and found similar results as
Nissen et al (Nissen 2007). We are not aware that the public was adequately informed about these results, otherwise the meta-analysis
by Nissen et al would not have aroused such a huge public interest. It is well know that glycosylated haemoglobin is a relatively poor
surrogate for cardiovascular outcomes and these data urgently suggest that we need to change the regulatory pathway for drugs for the
treatment of type 2 diabetes to make clinical outcomes, not surrogates, the primary endpoint (Rosen 2007). It would be prudent for
one of the biggest pharmaceutical companies in the world being committed to patient care to engage in relevant clinical studies of
patient-oriented outcomes from the very beginning on.
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D E C L A R A T I O N S O F I N T E R E S T
This review in part contributes to the ongoing critical appraisal of RCTs investigating the risk-benefit ratio of thiazolidinedione use by
the German Institute for Quality and Efficiency in Health Care (’Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
- IQWiG).
S O U R C E S O F S U P P O R T
Internal sources
• Heinrich-Heine University of Duesseldorf, Germany.
External sources
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The following changes to the published protocol with regards to ’types of intervention’ were implemented:
The following comparisons were acceptable for evaluation:
• rosiglitazone versus placebo;
• rosiglitazone versus another oral antidiabetic medication (meglitinide analogues, metformin, pioglitazone, sulphonylureas);
• rosiglitazone in combination with an oral antidiabetic medication or insulin versus a combination of an oral antidiabetic
medication or insulin (agents and treatment schemes had to be identical).
Excluded interventions:
Combination therapies consisting of different compounds in the treatment arms (for example rosiglitazone plus metformin versus
uptitration of metformin or rosiglitazone plus gliclazide versus gliclazide). Another Cochrane review will investigate rosiglitazone-
metformin combination therapies including different treatment regimens of these compounds. Furthermore, dipeptidyl peptidase-4
(DPP-4) inhibitors for type 2 diabetes mellitus are excluded, since these are the topic of another Cochrane review (Richter 2007), as
well as glucagon-like peptide analogues for type 2 diabetes mellitus (Cochrane review, Snaith 2007).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetes Mellitus, Type 2 [∗drug therapy]; Hypoglycemic Agents [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as
Topic; Thiazolidinediones [adverse effects; ∗therapeutic use]
MeSH check words
Adult; Female; Humans; Male
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